Methods of treatment of non-mycobacterium tuberculosis infections

The treatment difficulties of NTM infection were solved through oral treatment of eperborol, including use alone or in combination with other antibiotics, and the reduction of infection and enhancement of the immune system was achieved.

CN118984830APending Publication Date: 2024-11-19AN2 THERAPEUTICS INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202280091004.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-07
Filing Date
2022-05-18
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat non-tuberculous mycobacterium (NTM) infection in human subjects, and there is a lack of effective treatment methods.

Method used

Epetraborole is used as a therapeutic agent, and the doses of about 250 mg to about 1000 mg are administered orally, and are administered daily or every other day according to different treatment regimens until a positive therapeutic response is achieved. Eperborol can be used alone or in combination with other antibiotics such as ethambutol, azithromycin, clarithromycin, rifampin, etc.

Benefits of technology

A positive therapeutic response to NTM infection was achieved, reducing bacterial colony counts, reducing the severity of infection, and improving the symptoms of infection-related diseases, and improving the human immune system's ability to respond to infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004979094480000041
    Figure BDA0004979094480000041
  • Figure BDA0004979094480000081
    Figure BDA0004979094480000081
  • Figure BDA0004979094480000801
    Figure BDA0004979094480000801
Patent Text Reader

Abstract

The present invention relates to methods of effecting a positive therapeutic response against non-binding mycobacterium (NTM) infection by administering an oral dose of eponboro to a human subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 286,989, filed on December 7, 2021, the entire contents of which are incorporated herein by reference for all purposes. Background of the Invention

[0004] There is a need for improved methods of treating nontuberculous mycobacterium (NTM) infections in human subjects. SUMMARY OF THE INVENTION

[0006] In one aspect, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising: administering epetraborole to a human subject in need of treatment, a dosage regimen comprising: administering an oral dose of epetraborole of about 250 mg to about 1000 mg on the first day of the dosage regimen, and administering the oral dose every day or every other day, wherein the dosage regimen is continued until a positive therapeutic response is achieved. DETAILED DESCRIPTION OF THE INVENTION

[0008] I. Definitions

[0009] In order to more fully understand the present application, several definitions are set forth below. Such definitions are intended to encompass grammatical equivalents.

[0010] The term "about" associated with a reference value may include the value itself and a range of values ​​that are plus or minus 10%. For example, an amount of "about 10" includes 10 and any amount of 9-11. For example, the term "about" associated with a reference value may also include a range of values ​​that are plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the value.

[0011] Specific embodiments disclosed herein may be further limited in the claims using "consisting of" or "consisting essentially of" language. When used in a claim, whether filed as an amendment or added, the transitional term "consisting of" excludes any elements, steps, or ingredients not specified in the claim. The transitional term "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics. The embodiments of the present disclosure so claimed are inherently or expressly described and enabled herein.

[0012] The terms "a," "an," "the" and similar referents used in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0013] The following abbreviations are used: ADH = alcohol dehydrogenase; AE = adverse event; AESI = adverse event of special interest; AIDS = acquired immunodeficiency syndrome; ALIS = amikacin liposomal inhalation suspension; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ATS = American Thoracic Society; AUC = area under the concentration-time curve; AUC∞ = area under the concentration-time curve from time 0 to infinity; AUC0-24 = area under the concentration-time curve from time 0 to 24 hours; CD4 = cluster of differentiation 4; CDAD = Clostridioides difficile difficile-associated diarrhea; Clostridium difficile (C. difficile) = Clostridium difficile; CL = total body clearance from plasma; CLSI = Clinical and Laboratory Standards Institute; Cmax = maximum plasma drug concentration; Cmin = minimum plasma drug concentration; CRA = clinical research associate; CrCl = creatinine clearance; CRO = contract research organization; CT = computed tomography; CTA = clinical trial authorization; CTCAE = Common Terminology Criteria for Adverse Events; CYP = cytochrome P450; DSMB = data and safety monitoring board; ECG = electrocardiogram; eCRF = electronic case report form; EDC = electronic data capture; EIU = in utero exposure; EOT = end of therapy; ERS = European Respiratory Society; ESCMID = European Society of Clinical Microbiology and Infectious Diseases; FAS-PRO = full analysis set - patient-reported Results; FDA = Food and Drug Administration; FOCP = females of childbearing potential; GCP = good clinical practice; GI = gastrointestinal; HFM = hollow fiber macrophages; HIV = human immunodeficiency virus; ICF = informed consent; ICH = International Council for Harmonization; IDSA = Infectious Diseases Society of America; IEC = Independent Ethics Committee; IR = immediate release; IRB = Institutional Review Board; IRT = interactive response technique; ITT = intention to treat; IV = intravenous; LAR = legally authorized representative; LFU = late visit; Log = logarithmic; LPA = line probe assay; MAC = Mycobacterium avium complex; M. avium = Mycobacterium avium; M. chimaera = Mycobacterium chimaera; MCID = minimal clinically important difference; MedDRA = Medical Dictionary for Regulatory Activities; MIC = minimum inhibitory concentration; M. intracellulare (M.intracellulare) = Mycobacterium intracellulare; NADPH = nicotinamide adenine dinucleotide phosphate; NIMP = noninvestigational medical product; NTM = nontuberculous mycobacteria (1); OBR = optimized background regimen; PD = pharmacodynamics; P-gp = P-glycoprotein; PK = pharmacokinetic; PRO = patient-reported outcome; pT = preferred term; QD = once daily; QTcF = QT interval corrected using Fridericia's formula; RBC = red blood cells; rRNA = ribosomal ribonucleic acid; sAE = serious adverse event; SAP = statistical analysis plan; SOC = system organ class; SUSAR = suspected unexpected serious adverse reaction; t. 1 / 2 = elimination half-life; TEAE = treatment-emergent adverse event; T max = time to reach maximum plasma drug concentration; tRNA = transfer RNA; ULN = upper limit of normal; Vd = volume of distribution; V ss = apparent volume of distribution at steady state.

[0014] As used herein, "epebrol of the present invention" refers to epebrol, salts (eg, pharmaceutically acceptable salts), solvates, and hydrates of these compounds.

[0015] "Moiety" refers to a group of a molecule that is attached to the rest of the molecule.

[0016] symbol Whether used as a bond or shown perpendicular to a bond, it indicates the point at which the part shown is attached to the rest of the molecule.

[0017] As used herein, IC50 refers to the amount, concentration or dose of a particular test compound that achieves 50% inhibition of the maximal response in an assay measuring that response.

[0018] As used herein, EC50 refers to the dose, concentration or amount of a particular test compound that elicits a dose-dependent response that is 50% of the maximal expression of a particular response induced, stimulated or enhanced by the particular test compound.

[0019] As used herein, the term "positive therapeutic response" refers to reducing or improving or eliminating the progression, severity and / or effects associated with an infection described herein, or improving an infection condition, or improving a disease associated with an infection, or increasing the response of a human subject's immune system to an infection, or improving one or more symptoms (preferably, one or more discernible symptoms) of an infection described herein caused by the administration of one or more therapies. In a specific embodiment, the term "positive therapeutic response" refers to improving at least one measurable physical parameter of an infection described herein, such as colony count, degree of infection, or severity of infection. In other embodiments, the term "positive therapeutic response" refers to physically inhibiting the progression of an infection described herein by, for example, stabilizing discernible symptoms, physiologically by, for example, stabilizing physical parameters, or both. In other embodiments, the term "positive therapeutic response" refers to an increase in the immune system response of a human subject. In an exemplary embodiment, achieving a positive therapeutic response to an infection described herein provides improvement or no progression of an infection-related disease, and / or improvement or no progression of symptoms associated with an infection. For example, achieving a positive therapeutic response to an infection described herein refers to one or more of the following: (1) a reduction in bacterial colony counts; (2) a reduction in the extent of infection; (3) a reduction in the severity of infection; and (4) some relief of one or more other symptoms associated with a disease or condition. In some embodiments, achieving a positive therapeutic response to an infection described herein involves administering a composition described herein for a predetermined time period, stopping administration of another specific time period, and resuming administration of a composition described herein for another specific time period. In some embodiments, achieving a positive therapeutic response to an infection described herein involves administering a composition described herein until one of the responses described herein is achieved, suspending administration of a composition described herein while continuing to observe such a positive therapeutic response, and resuming administration of a composition described herein if such a positive therapeutic response is observed to have stopped. In an exemplary embodiment, achieving a positive therapeutic response is treating an infection described herein. In an exemplary embodiment, achieving a positive therapeutic response is treating a disease described herein.

[0020] A positive therapeutic response of the present invention includes a "therapeutically effective amount" of the drug used. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.

[0021] A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects.

[0022] As used herein, the term "fasting condition" may refer to when a human subject has not eaten for at least 1 hour before study drug administration, or when a human subject has not eaten for at least 2 hours after study drug administration, or when a human subject has not eaten for at least 1 hour before study drug administration and at least 2 hours after study drug administration.

[0023] As used herein, the term "need for treatment" may refer to a human subject suffering from an infection as described herein, such as an NTM infection, by clinical assessment and / or microbiological assessment and / or radiological assessment. As used herein, the term "need for treatment" may refer to when a human subject has an infection as described herein, such as an NTM infection, by microbiological assessment and / or radiological assessment. As used herein, the term "need for treatment" may refer to a human subject suffering from an infection as described herein, such as an NTM infection, by microbiological assessment. As used herein, the need for treatment may be assessed by analyzing a sputum sample, as described herein. As used herein, the need for treatment may be assessed by analyzing a deep bronchial sample, as described herein. As used herein, the need for treatment may be assessed by radiographic analysis of a human subject as described herein. As used herein, the need for treatment may be assessed by a computed tomography (CT) scan of the chest of a human subject as described herein. As used herein, the need for treatment may be assessed by a computed tomography (CT) scan of the lungs of a human subject as described herein.

[0024] The amount of certain compounds described herein provided to a human subject can depend on the body weight of the human subject. The body weight of a human subject can be obtained by a person, such as a medical professional (eg, a doctor or nurse), or a human subject by conventional and commercial means.

[0025] The terms "patient" and "human subject" are used interchangeably herein.

[0026] II. Overview

[0027] The present invention provides methods of achieving a positive therapeutic response against nontuberculous mycobacterium (NTM) infection by oral administration of epaborole according to the dosage regimen described herein.

[0028] III. Eperborole

[0029] Iperborole has the following structure:

[0030]

[0031] Iperborole can be produced by methods such as those disclosed in PCT Patent Publication No. WO 2008 / 157726 (PCT Patent Application PCT / US2008 / 07550); U.S. Patent No 7,816,344 (U.S. Patent Application 12 / 142,692); PCT Patent Publication No. WO 2011 / 127143 (PCT Patent Application PCT / US2011 / 031384); and U.S. Patent No 9,243,003 (U.S. Patent Application 13 / 639,594), all of which are expressly incorporated herein by reference.

[0032] Iperborole can form hydrates with water, solvates with alcohols such as methanol, ethanol, propanol, etc.; adducts with amino compounds such as ammonia, methylamine, ethylamine, etc.; adducts with acids such as formic acid, acetic acid, etc.; and complexes with ethanolamine, quinoline, amino acids, etc.

[0033] In an exemplary embodiment, the present invention provides ipeborole or a salt, hydrate or solvate thereof, or a combination thereof. In an exemplary embodiment, the present invention provides ipeborole or a salt, hydrate or solvate thereof. In an exemplary embodiment, the present invention provides ipeborole or a salt thereof. In an exemplary embodiment, the salt is a pharmaceutically acceptable salt. In an exemplary embodiment, the present invention provides the hydrochloride salt of ipeborole. In an exemplary embodiment, the present invention provides ipeborole or a hydrate thereof. In an exemplary embodiment, the present invention provides ipeborole or a solvate thereof. In an exemplary embodiment, ipeborole is ipeborole hydrochloride.

[0034] In an exemplary embodiment, iperbrol is administered in an amount of about 200 mg to about 1,100 mg. In an exemplary embodiment, iperbrol is administered in an amount of about 250 mg to about 1,000 mg. In an exemplary embodiment, iperbrol is administered in an amount of about 200 mg to about 300 mg, or about 225 mg to about 275 mg, or about 240 mg or about 260 mg, or about 250 mg, or 250 mg. In an exemplary embodiment, iperbrol is administered in an amount of about 400 mg to about 600 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 490 mg or about 510 mg, or about 500 mg, or 500 mg. In an exemplary embodiment, iperbole is administered in an amount of about 600 mg to about 900 mg, or about 650 mg to about 850 mg, or about 700 mg to about 800 mg, or about 725 mg or about 775 mg, or about 740 mg or about 760 mg, or about 750 mg, or 750 mg. In an exemplary embodiment, iperbole is administered in an amount of about 900 mg to about 1,100 mg, or about 925 mg to about 1,075 mg, or about 950 mg to about 1,050 mg, or about 975 mg or about 1,025 mg, or about 990 mg or about 1,010 mg, or about 1,000 mg, or 1,000 mg. For any of the embodiments in this paragraph, iperbole is suitable for oral administration. For any of the embodiments in this paragraph, ipeborole is in a unit dosage suitable for oral administration, such as a single pill or capsule or tablet containing about 475 mg to about 525 mg ipeborole.

[0035] Once prepared, eperborole can be administered to a human subject as described herein, for example, at a dosage regimen described herein.

[0036] III.a) Pharmaceutical compositions and drug administration

[0037] Iperborole can be incorporated into a pharmaceutical composition suitable for administration to a human subject according to the dosage regimen described herein. Typically, the pharmaceutical composition comprises Iperborole and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, which are physiologically compatible and suitable for administration to a subject for use in the methods described herein.

[0038] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose.

[0039] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a glidant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and silicon dioxide. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and colloidal silicon dioxide.

[0040] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a disintegrant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and sodium. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and croscarmellose sodium.

[0041] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and magnesium stearate.

[0042] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a glidant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and silicon dioxide. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and colloidal silicon dioxide.

[0043] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a disintegrant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and sodium. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and croscarmellose sodium.

[0044] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and magnesium stearate.

[0045] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a glidant and a disintegrant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and silicon dioxide and sodium. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and colloidal silicon dioxide and croscarmellose sodium.

[0046] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a glidant and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and silicon dioxide and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and colloidal silicon dioxide and magnesium stearate.

[0047] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a disintegrant and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and sodium and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and croscarmellose sodium and magnesium stearate.

[0048] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a glidant and a disintegrant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and silicon dioxide and sodium. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and colloidal silicon dioxide and croscarmellose sodium.

[0049] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a glidant and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and silicon dioxide and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and colloidal silicon dioxide and magnesium stearate.

[0050] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a glidant and a disintegrant and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and silicon dioxide and sodium and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and colloidal silicon dioxide and croscarmellose sodium and magnesium stearate.

[0051] In an exemplary embodiment, the pharmaceutical composition comprises eperborole and a filler and a glidant and a disintegrant and a lubricant. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and cellulose and silicon dioxide and sodium and stearate. In an exemplary embodiment, the pharmaceutical composition comprises eperborole and microcrystalline cellulose and colloidal silicon dioxide and croscarmellose sodium and magnesium stearate.

[0052] In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 200 mg to about 1,100 mg. In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 250 mg to about 1,000 mg. In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 200 mg to about 300 mg, or about 225 mg to about 275 mg, or about 240 mg or about 260 mg, or about 250 mg, or 250 mg. In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 400 mg to about 600 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 490 mg or about 510 mg, or about 500 mg, or 500 mg. In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 600 mg to about 900 mg, or about 650 mg to about 850 mg, or about 700 mg to about 800 mg, or about 725 mg or about 775 mg, or about 740 mg or about 760 mg, or about 750 mg, or 750 mg. In an exemplary embodiment, the pharmaceutical composition comprises an amount of eperborole of about 900 mg to about 1,100 mg, or about 925 mg to about 1,075 mg, or about 950 mg to about 1,050 mg, or about 975 mg or about 1,025 mg, or about 990 mg or about 1,010 mg, or about 1,000 mg, or 1,000 mg. For any of the embodiments in this paragraph, the pharmaceutical composition is suitable for oral administration. For any of the embodiments in this paragraph, the pharmaceutical composition is a unit dosage suitable for oral administration, such as a single pill or capsule or tablet containing about 475 mg to about 525 mg of eperborole. For any of the embodiments in this paragraph, the pharmaceutical composition comprises eperborole hydrochloride.

[0053] Eperborole can be administered by various methods known in the art. In an exemplary embodiment, the route / mode of administration is oral. As will be appreciated by those skilled in the art, the route / mode of administration can vary depending on the desired results.

[0054] IV. Treatment of other nontuberculous mycobacteria

[0055] In an exemplary embodiment, eperborole can be administered with other compounds to achieve a positive therapeutic response against nontuberculous mycobacterial infection. Examples of these other compounds are provided below: Ethambutol

[0056] Ethambutol has the following structure:

[0057]

[0058] Ethambutol is produced commercially by a number of manufacturers, such as Barr Laboratories, Akorn, Sanofi, Cadila, Lupin and Delmar. Ethambutol hydrochloride tablets suitable for oral administration are available in 100 mg and 400 mg forms.

[0059] Paragraph Z: In an exemplary embodiment, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg, or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg, or 25 mg / kg.

[0060] Paragraph Y: In an exemplary embodiment, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered daily at an oral dose of about 13 mg / kg to about 17 mg / kg, or about 15 mg / kg, administered daily. In an exemplary embodiment, about 600 mg to about 2000 mg, or about 600 mg to about 800 mg, or about 800 mg to about 1,000 mg, or about 1,000 mg to about 1,200 mg, or about 1,200 mg to about 1,400 mg, or about 1,400 mg to about 1,600 mg, or about 1,600 mg to about 1,800 mg, or about 1,800 mg to about 2,000 mg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered daily.

[0061] Paragraph X: In an exemplary embodiment, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 23 mg / kg to about 27 mg / kg or about 25 mg / kg, three days per week. In an exemplary embodiment, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 900 mg to about 3,400 mg, or about 900 mg to about 1,200 mg, or about 1,200 mg to about 1,500 mg, or about 1,500 mg to about 1,800 mg, or about 1,800 mg to about 2,100 mg, or about 2,100 mg to about 2,400 mg, 2,400 mg to about 2,700 mg, or about 2,700 mg to about 3,000 mg, or about 3,000 mg to about 3,400 mg, three days per week.

[0062] Clarithromycin or Azithromycin

[0063] Azithromycin is commercially produced by a number of manufacturers, such as Pfizer, Sandoz, Teva, Alembic, Lupin, Fresenius, Hospira, and Aurobindo. Azithromycin tablets of 250 mg, 500 mg, and 600 mg are available for oral administration. Azithromycin is available in 500 mg / vial for intravenous administration. A 100 mg / 5 mL azithromycin suspension is available for oral administration.

[0064] Paragraph W: In an exemplary embodiment, azithromycin is administered at an oral dose of about 200 mg to about 550 mg, or about 200 mg to about 300 mg, or about 225 mg to about 275 mg, or about 250 mg, or about 250 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 500 mg or 500 mg. In an exemplary embodiment, azithromycin or a hydrate, solvate, or a pharmaceutically acceptable salt thereof is administered at an oral dose of about 200 mg to about 550 mg daily or three days per week.

[0065] Paragraph V: In an exemplary embodiment, an oral dose of about 225 mg to about 275 mg, or about 250 mg of azithromycin or a hydrate, solvate, or a pharmaceutically acceptable salt thereof is administered daily. In an exemplary embodiment, an oral dose of about 475 mg to about 525 mg, or about 500 mg of azithromycin or a hydrate, solvate, or a pharmaceutically acceptable salt thereof is administered daily.

[0066] Paragraph U: In an exemplary embodiment, an oral dose of about 475 mg to about 525 mg, or about 500 mg, of azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered three days per week.

[0067] Clarithromycin is produced commercially by a number of manufacturers, such as Sandoz, Century Pharmaceuticals, Teva, Wockhardt, and Alembic. 250 mg and 500 mg clarithromycin tablets are available for oral administration. 125 mg / 5 mL or 250 mg / 5 mL clarithromycin suspensions are available for oral administration.

[0068] Paragraph T: In an exemplary embodiment, clarithromycin is administered at an oral dose of about 400 mg to about 600 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 500 mg, or 500 mg, or about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg. In an exemplary embodiment, clarithromycin is administered at an oral dose of about 950 mg to about 1,050 mg per day, or about 1,000 per day, or about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day. In an exemplary embodiment, an oral dose of about 900 mg to about 1,100 mg, or about 975 mg, or about 1,025 mg, or about 1,000 mg, or 1,000 mg of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily or three times a week. In an exemplary embodiment, an oral dose of about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily or three times a week.

[0069] Paragraph S: In an exemplary embodiment, an oral dose of about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily. In an exemplary embodiment, an oral dose of about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily.

[0070] Paragraph R: In an exemplary embodiment, an oral dose of about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered three days per week. In an exemplary embodiment, an oral dose of about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered three days per week.

[0071] Rifampicin

[0072] Rifampicin, also known as rifampicin, is commercially produced by many manufacturers, such as Akorn, Lupin, EpicPharma, Oxford, Fresenius, Sanofi Aventis, Novartis, Otto Brandes, rudavis Labs, and Sichuan Long March Pharma. 150 mg and 300 mg rifampicin capsules are available for oral administration. 600 mg / vial of rifampicin is available for intravenous administration.

[0073] Paragraph Q: In an exemplary embodiment, rifampicin is administered at an oral dose of about 5 mg / kg to about 15 mg / kg, or about 9 mg / kg, or about 11 mg / kg, or about 10 mg / kg, or 10 mg / kg. In an exemplary embodiment, rifampicin is administered at an oral dose of about 350 mg to about 700 mg, or about 350 to about 500 mg, or about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg or 450 mg, or about 500 mg to about 700 mg, or about 550 mg to about 650 mg, or about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg or 600 mg. In an exemplary embodiment, an oral dose of about 9 mg / kg, or about 11 mg / kg, or about 10 mg / kg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily or three days per week.

[0074] Paragraph P: In an exemplary embodiment, an oral dose of about 9 mg / kg, or about 11 mg / kg, or about 10 mg / kg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily. In an exemplary embodiment, an oral dose of about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily. In an exemplary embodiment, an oral dose of about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily.

[0075] Paragraph O: In an exemplary embodiment, an oral dose of about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered three days per week.

[0076] Rifabutin

[0077] Rifabutin is produced commercially by a number of manufacturers, such as Pfizer, Chongqing Huapont Pharma, Lupin, Novitium Pharma and Guangzhou Tosun Pharma. Rifabutin capsules of 150 mg are available for oral administration.

[0078] Paragraph N: In an exemplary embodiment, rifabutin is administered at an oral dose of about 100 mg to about 350 mg, or about 100 to about 200 mg, or about 125 mg to about 175 mg, or about 140 mg to about 160 mg, or about 150 mg or 150 mg, or about 250 mg to about 350 mg, or about 275 mg to about 325 mg, or about 290 mg to about 310 mg, or about 300 mg, or 300 mg.

[0079] Paragraph M: In an exemplary embodiment, an oral dose of about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg of rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily. In an exemplary embodiment, an oral dose of about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered daily.

[0080] Paragraph L: In an exemplary embodiment, an oral dose of about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifabutin or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered three days per week.

[0081] Amikacin for injection

[0082] Amikacin is commercially available in injectable formulations from a number of manufacturers, such as Teva, Hospira, Abbott Laboratories, Apothecon, and Fresenius. Amikacin sulfate is available in 50 mg / mL and 250 mg / mL for intravenous administration.

[0083] Paragraph K: In an exemplary embodiment, the intravenous dose of amikacin is about 8 mg / kg or about 17 mg / kg, or about 10 mg / kg or about 15 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 10 mg / kg, or 10 mg / kg, or about 15 mg / kg, or 15 mg / kg, administered daily.

[0084] Paragraph J: In an exemplary embodiment, an intravenous dose of amikacin of about 13 mg / kg, or about 27 mg / kg, or about 15 mg / kg, or about 25 mg / kg, or about 15 mg / kg, or 15 mg / kg, or about 25 mg / kg, or 25 mg / kg is administered three days per week.

[0085] Inhaled amikacin

[0086] Amikacin liposomal suspension for inhalation Commercially available from Insmed, Inc., a 590 mg / 8.4 mL inhalation formulation is available.

[0087] Paragraph I: In an exemplary embodiment, the inhaled dose of amikacin is about 580 mg to about 600 mg, or about 590 mg, or 590 mg, administered daily.

[0088] Ciprofloxacin

[0089] Ciprofloxacin is produced commercially by a number of manufacturers, such as Bayer, Dr. Reddy's, Aurobindo, Taro, and Watson. 100 mg, 250 mg, and 500 mg ciprofloxacin tablets are available for oral administration.

[0090] Linezolid

[0091] Linezolid is produced commercially by a number of manufacturers, such as Alembic, Pfizer, Glenmark and Zydus. Linezolid is available as 600 mg tablets for oral administration.

[0092] Moxifloxacin

[0093] Moxifloxacin is produced commercially by a number of manufacturers, such as Teva, Dr. Reddy's and Aurobindo. Moxifloxacin hydrochloride tablets of 400 mg are available for oral administration.

[0094] Streptomycin

[0095] Streptomycin is produced commercially by Xgen Pharmaceuticals. Streptomycin sulfate is available as 1 g / vial for intravenous administration.

[0096] Tigecycline

[0097] Tigecycline is produced commercially by a number of manufacturers, such as Prism, Sandoz, Fresenius, and Apotex. Tigecycline is available in 50 mg / vial for intravenous administration.

[0098] Synergistic effect with epaborole and ethambutol

[0099] A synergistic effect of epaborole and ethambutol has been discovered that may lead to more effective treatment of NTM infections.

[0100] V. Administration / Dosage Regimens Using Eperborole

[0101] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response for a nontuberculous mycobacterium (NTM) infection, comprising administering ipebobrol or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. For any embodiment in Part V, ipebobrol is ipebobrol hydrochloride. In an exemplary embodiment, ipebobrol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered in an amount as described herein. In an exemplary embodiment, for any method described herein, the positive therapeutic response is treatment of a nontuberculous mycobacterium (NTM) infection. In an exemplary embodiment, for any dosage regimen described herein, the positive therapeutic response is treatment of a nontuberculous mycobacterium (NTM) infection. In an exemplary embodiment, for any dosage regimen described herein, ipebobrol is ipebobrol hydrochloride. For any embodiment in Part V, ipebobrol is ipebobrol hydrochloride.

[0102] In an exemplary embodiment, the components described herein can be used to achieve a positive therapeutic response for nontuberculous mycobacteria (NTM) infection. In an exemplary embodiment, the combination of components described herein can be used to achieve a positive therapeutic response for nontuberculous mycobacteria (NTM) infection. In an exemplary embodiment, the ipeborole composition is administered according to the methods described herein to achieve a positive therapeutic response for nontuberculous mycobacteria (NTM) infection. In an exemplary embodiment, an infection with nontuberculous mycobacteria (NTM) can be treated with ipeborole (ipeborole).

[0103] Vi) Eperborole & Ethambutol

[0104] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment ipeboborot or a hydrate, solvate or pharmaceutically acceptable salt thereof and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, ipeboborot or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg, or 25 mg / kg.

[0105] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: administering an oral dose of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein daily or every other day; and administering an oral dose of ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein daily or three days per week.

[0106] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 250 mg to about 1000 mg of eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 10 mg / kg to about 30 mg / kg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily or three days per week. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg or about 500 mg of eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 13 mg / kg to about 17 mg / kg or about 15 mg / kg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 600 mg to about 2000 mg, or about 600 mg to about 800 mg, or about 800 mg to about 1,000 mg, or about 1,000 mg to about 1,200 mg, or about 1,200 mg to about 1,400 mg, or about 1,400 mg to about 1,600 mg, or about 1,600 mg to about 1,800 mg, or about 1,800 mg to about 2,000 mg, of ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 23 mg / kg to about 27 mg / kg, or about 25 mg / kg, of ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 900 mg to about 3,400 mg, or about 900 mg to about 1,200 mg, or about 1,200 mg to about 1,500 mg, or about 1,500 mg to about 1,800 mg, or about 1,800 mg to about 2,100 mg, or about 2,100 mg to about 2,400 mg, or about 2,400 mg to about 2,700 mg, or about 2,700 mg to about 3,000 mg, or about 3,000 mg to about 3,400 mg of ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week.

[0107] V.ii.) Eperborole & Azithromycin

[0108] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and azithromycin is administered at an oral dose of about 200 mg to about 550 mg, or about 200 mg to about 300 mg, or about 225 mg to about 275 mg, or about 250 mg, or about 250 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 500 mg, or 500 mg.

[0109] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an oral dose of azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or three days per week.

[0110] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 250 mg to about 1000 mg of iperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 200 mg to about 550 mg of azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily or three days per week. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of iperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 225 mg to about 275 mg, or about 250 mg of azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of ipaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 475 mg to about 525 mg, or about 500 mg of azithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of ipaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 475 mg to about 525 mg, or about 500 mg of azithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week.

[0111] V.iii.) Eperborole & Clarithromycin

[0112] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg, and clarithromycin is administered at an oral dose of about 400 mg to about 600 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 500 mg, or 500 mg, or about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg. In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg, and clarithromycin is administered at an oral dose of about 950 mg to about 1,050 mg per day, or about 1,000 per day, or about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day.

[0113] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an oral dose of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or three days per week.

[0114] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 250 mg to about 1000 mg of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 900 mg to about 1,100 mg, or about 975 mg, or about 1,025 mg, or about 1,000 mg, or 1,000 mg of clarithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily or three days per week.

[0115] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 250 mg to about 1000 mg of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 400 mg to about 600 mg twice daily, or about 450 mg to about 550 mg twice daily, or about 475 mg to about 525 mg twice daily, or about 500 mg twice daily, or 500 mg twice daily of clarithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily or three days per week. In an exemplary embodiment, the dosage regimen comprises about 475 mg to about 525 mg, or about 500 mg oral doses of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg oral doses of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises about 475 mg to about 525 mg, or about 500 mg oral doses of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and about 900 mg to about 1,100 mg, or about 975 mg or about 1,025 mg, or about 1,000 mg, or 1,000 mg oral doses of clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 400 mg to about 600 mg twice daily, or about 450 mg to about 550 mg twice daily, or about 475 mg to about 525 mg twice daily, or about 500 mg twice daily, or 500 mg twice daily of clarithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily, and an oral dose of about 400 mg to about 600 mg twice daily, or about 450 mg to about 550 mg twice daily, or about 475 mg to about 525 mg twice daily, or about 500 mg twice daily, or 500 mg twice daily of clarithromycin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week.

[0116] V.iv.) Eperborole & Rifampicin

[0117] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment ipaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, ipaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and rifampicin is administered at an oral dose of about 5 mg / kg to about 15 mg / kg, or about 9 mg / kg or about 11 mg / kg, or about 10 mg / kg or 10 mg / kg. In an exemplary embodiment, ipeborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg, and rifampicin is administered at an oral dose of about 350 mg to about 700 mg, or about 350 to about 500 mg, or about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg or 450 mg, or about 500 mg to about 700 mg, or about 550 mg to about 650 mg, or about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg, or 600 mg.

[0118] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an oral dose of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or three days per week.

[0119] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 250 mg to about 1000 mg of iperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily, and about 9 mg / kg or about 11 mg / kg, or about 10 mg / kg of rifampicin or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily or three days per week. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of iperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily, and about 9 mg / kg or about 11 mg / kg or about 10 mg / kg of rifampicin or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered daily.

[0120] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg, of rifampicin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily.

[0121] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of ipaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg of ipaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg of rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week.

[0122] Vv) Eperborole & Rifabutin

[0123] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof and rifabutin or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0124] In an exemplary embodiment, epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and rifabutin is administered at an oral dose of about 100 mg to about 350 mg, or about 100 to about 200 mg, or about 125 mg to about 175 mg, or about 140 mg to about 160 mg, or about 150 mg or 150 mg, or about 250 mg to about 350 mg, or about 275 mg to about 325 mg, or about 290 mg to about 310 mg, or about 300 mg or 300 mg.

[0125] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an oral dose of rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or three days per week.

[0126] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of epaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and an oral dose of about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg, of rifabutin, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily.

[0127] In an exemplary embodiment, the dosage regimen comprises about 475 mg to about 525 mg, or about 500 mg oral doses of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg oral doses of rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily. In an exemplary embodiment, the dosage regimen comprises about 475 mg to about 525 mg, or about 500 mg oral doses of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg oral doses of rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered three days per week.

[0128] V.vi.) Eperborole & Ethambutol & Rifampicin

[0129] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof, and rifampicin or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0130] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg or 25 mg / kg. Oral doses are administered, and rifampicin is administered at an oral dose of about 5 mg / kg to about 15 mg / kg, or about 9 mg / kg or about 11 mg / kg, or about 10 mg / kg or 10 mg / kg, or about 350 mg to about 700 mg, or about 350 to about 500 mg, or about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg or 450 mg, or about 500 mg to about 700 mg, or about 550 mg to about 650 mg, or about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg or 600 mg.

[0131] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day; and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and rifampicin is administered according to paragraph P.

[0132] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and rifampicin administered in accordance with paragraph P.

[0133] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and rifampicin is administered according to paragraph O.

[0134] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, and rifampicin is administered according to paragraph O.

[0135] V.vii.) Eperborole & Ethambutol & Rifabutin

[0136] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof, and rifabutin or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0137] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg or 15 mg / kg, Or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg or 25 mg / kg oral dose, and rifabutin is administered at an oral dose of about 100 mg to about 350 mg, or about 100 to about 200 mg, or about 125 mg to about 175 mg, or about 140 mg to about 160 mg, or about 150 mg, or 150 mg, or about 250 mg to about 350 mg, or about 275 mg to about 325 mg, or about 290 mg to about 310 mg, or about 300 mg or 300 mg.

[0138] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and rifabutin is administered according to paragraph M.

[0139] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and rifabutin administered in accordance with paragraph M.

[0140] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and rifabutin is administered according to paragraph L.

[0141] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and rifabutin administered in accordance with paragraph L.

[0142] V.viii.) Eperborole & Ethambutol & Azithromycin

[0143] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0144] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg. kg or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg or 25 mg / kg, and azithromycin is administered at an oral dose of about 200 mg to about 550 mg, or about 200 mg to about 300 mg, or about 225 mg to about 275 mg, or about 250 mg or about 250 mg, or about 450 mg to about 550 mg, or about 475 mg to about 525 mg, or about 500 mg or 500 mg.

[0145] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, and azithromycin administered according to paragraph V.

[0146] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and azithromycin administered in accordance with paragraph V.

[0147] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and azithromycin is administered according to paragraph U.

[0148] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and azithromycin administered in accordance with paragraph U.

[0149] V.ix.) Eperborole & Ethambutol & Clarithromycin

[0150] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0151] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg or about 20 mg / kg. The invention relates to an oral dosage of about 15 mg / kg, or about 23 mg / kg, or about 27 mg / kg, or about 25 mg / kg or 25 mg / kg, and clarithromycin is administered at an oral dosage of about 950 mg to about 1,050 mg per day, or about 1,000 per day, or about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day.

[0152] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and clarithromycin is administered according to paragraph S.

[0153] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, is administered in accordance with paragraph X, and clarithromycin is administered in accordance with paragraph S.

[0154] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and clarithromycin is administered according to paragraph R.

[0155] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, is administered in accordance with paragraph X, and clarithromycin is administered in accordance with paragraph R.

[0156] Vx) Eperborole & Ethambutol & Rifampicin & Azithromycin

[0157] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0158] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, and azithromycin is administered according to paragraph V.

[0159] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampin is administered according to paragraph O, and azithromycin is administered according to paragraph V.

[0160] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, rifampicin administered in accordance with paragraph P, and azithromycin administered in accordance with paragraph V.

[0161] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered in accordance with paragraph X, rifampicin is administered in accordance with paragraph O, and azithromycin is administered in accordance with paragraph V.

[0162] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, and azithromycin is administered according to paragraph U.

[0163] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampin is administered according to paragraph O, and azithromycin is administered according to paragraph U.

[0164] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, and azithromycin is administered according to paragraph U.

[0165] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, and azithromycin is administered according to paragraph U.

[0166] V.xi.) Eperborole & Ethambutol & Rifampicin & Clarithromycin

[0167] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0168] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg or 25 mg / kg, and rifampicin is administered at an oral dose of about 5 mg / kg to about 15 mg / kg, or about 9 mg / kg or about 11 mg / kg, or about 10 mg / kg or 10 mg / kg. g / kg, or about 350 mg to about 700 mg, or about 350 to about 500 mg, or about 425 mg to about 475 mg, or about 440 mg to about 460 mg, or about 450 mg or 450 mg, or about 500 mg to about 700 mg, or about 550 mg to about 650 mg, or about 575 mg to about 625 mg, or about 590 mg to about 610 mg, or about 600 mg or 600 mg oral dose, and clarithromycin is administered at an oral dose of about 950 mg to about 1,050 mg per day, or about 1,000 per day, or about 400 mg to about 600 mg twice a day, or about 450 mg to about 550 mg twice a day, or about 475 mg to about 525 mg twice a day, or about 500 mg twice a day, or 500 mg twice a day.

[0169] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, and clarithromycin is administered according to paragraph S.

[0170] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, and clarithromycin is administered according to paragraph S.

[0171] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, and clarithromycin is administered according to paragraph S.

[0172] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, and clarithromycin is administered according to paragraph S.

[0173] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, and clarithromycin is administered according to paragraph R.

[0174] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, and clarithromycin is administered according to paragraph R.

[0175] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, and clarithromycin is administered according to paragraph R.

[0176] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, and clarithromycin is administered according to paragraph R.

[0177] V.xii.) Eperborole & Ethambutol & Rifabutin & Azithromycin

[0178] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0179] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, and azithromycin is administered according to paragraph V.

[0180] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof administered daily at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof administered in accordance with paragraph Y, rifabutin administered in accordance with paragraph L, and azithromycin administered in accordance with paragraph V.

[0181] In an exemplary embodiment, the dosage regimen comprises epaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, rifabutin administered in accordance with paragraph M, and azithromycin administered in accordance with paragraph V.

[0182] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, rifabutin administered in accordance with paragraph L, and azithromycin administered in accordance with paragraph V.

[0183] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, and azithromycin is administered according to paragraph U.

[0184] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, and azithromycin is administered according to paragraph U.

[0185] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, and azithromycin is administered according to paragraph U.

[0186] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, and azithromycin is administered according to paragraph U.

[0187] V.xiii.) Eperborole & Ethambutol & Rifabutin & Clarithromycin

[0188] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0189] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, and clarithromycin is administered according to paragraph S.

[0190] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, and clarithromycin is administered according to paragraph S.

[0191] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, and clarithromycin is administered according to paragraph S.

[0192] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, and clarithromycin is administered according to paragraph S.

[0193] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, and clarithromycin is administered according to paragraph R.

[0194] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, and clarithromycin is administered according to paragraph R.

[0195] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, and clarithromycin is administered according to paragraph R.

[0196] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, and clarithromycin is administered according to paragraph R.

[0197] V.xiv.) Ipeborole & Amikacin

[0198] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, ipeborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and the intravenous dose of amikacin is about 8 mg / kg to about 30 mg / kg, or about 8 mg / kg or about 17 mg / kg, or about 10 mg / kg or about 15 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 10 mg / kg or 10 mg / kg, or about 15 mg / kg or 15 mg / kg, or about 13 mg / kg or about 27 mg / kg, or about 15 mg / kg or about 25 mg / kg, or about 15 mg / kg or 15 mg / kg, or about 25 mg / kg or 25 mg / kg.

[0199] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an intravenous dose of amikacin as described herein, administered daily or three days per week.

[0200] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and an intravenous dose of about 8 mg / kg, or about 17 mg / kg, or about 10 mg / kg, or about 15 mg / kg, or about 13 mg / kg, or about 17 mg / kg, or about 10 mg / kg, or about 10 mg / kg, or about 15 mg / kg, or 15 mg / kg of amikacin, administered daily.

[0201] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and an intravenous dose of about 13 mg / kg, or about 27 mg / kg, or about 15 mg / kg, or about 25 mg / kg, or about 15 mg / kg, or about 25 mg / kg, or 25 mg / kg of amikacin, administered three days per week.

[0202] V.xv.) Iperborole & inhaled amikacin

[0203] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeboborot or a hydrate, solvate or pharmaceutically acceptable salt thereof and inhaled amikacin or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, ipeboborot or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and the inhaled dose of amikacin is about 580 mg to about 600 mg. Or about 590 mg, or 590 mg.

[0204] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dosage regimen comprising: an oral dose of epeboracol or a hydrate, solvate or pharmaceutically acceptable salt thereof as described herein, administered daily or every other day; and an inhaled dose of amikacin as described herein, administered daily.

[0205] In an exemplary embodiment, the dosage regimen comprises an oral dose of about 475 mg to about 525 mg, or about 500 mg, of eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered daily; and about 580 mg to about 600 mg, or about 590 mg, or 590 mg, of amikacin, administered daily by inhalation.

[0206] V.xvi.) Eperborole & Ethambutol & Amikacin

[0207] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0208] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg or 500 mg, and ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg, or about 25 mg / kg, and amikacin is administered at an oral dose of about 8 mg / kg to about 30 mg / kg, or about 8 mg / kg or about 17 mg / kg, or about 10 mg / kg or about 15 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 10 mg / kg, or 10 mg / kg, or about 15 mg / kg, or 15 mg / kg, or about 13 mg / kg or about 27 mg / kg, or about 15 mg / kg or about 25 mg / kg, or about 15 mg / kg, or 15 mg / kg, or about 25 mg / kg, or 25 mg / kg, or 25 mg / kg, intravenously.

[0209] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and amikacin is administered according to paragraph K.

[0210] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and amikacin administered in accordance with paragraph K.

[0211] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and amikacin is administered according to paragraph J.

[0212] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and amikacin administered in accordance with paragraph J.

[0213] V.xvii.) Eperborole & ethambutol & inhaled amikacin

[0214] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0215] In an exemplary embodiment, eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 250 mg to about 1000 mg, or about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg, or about 13 mg / kg or about 17 mg / kg, or about 15 mg / kg, or 15 mg / kg, or about 23 mg / kg or about 27 mg / kg, or about 25 mg / kg, or 25 mg / kg, and amikacin is administered at an inhaled dose of about 580 mg to about 600 mg, or about 590 mg, or 590 mg.

[0216] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, and amikacin is administered according to paragraph I.

[0217] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered in accordance with paragraph X, and amikacin administered in accordance with paragraph I.

[0218] V.xviii.) Eperborole & Ciprofloxacin

[0219] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering ipeborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and ciprofloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0220] V.xix.) Eperborole & Ethambutol & Ciprofloxacin

[0221] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and ciprofloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0222] V.xx.) Eperborole & Linezolid

[0223] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and linezolid or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0224] V.xxi.) Eperborole & Ethambutol & Linezolid

[0225] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and linezolid or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0226] V.xxii.) Iperborole & moxifloxacin

[0227] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof and moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0228] V.xxiii.) Eperborole & Ethambutol & Moxifloxacin

[0229] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0230] V.xxiv.) Eperborole & Streptomycin

[0231] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0232] V.xxv.) Eperborole & Ethambutol & Streptomycin

[0233] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0234] V.xxvi.) Eperborole & tigecycline

[0235] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, and tigecycline or a hydrate, solvate or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0236] V.xxvii.) Eperborole & Ethambutol & Tigecycline

[0237] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and tigecycline or a hydrate, solvate, or pharmaceutically acceptable salt thereof to a human subject in need of treatment, thereby achieving a positive therapeutic response.

[0238] V.xxviii.) Eperborole & ethambutol & rifampicin & azithromycin & amikacin

[0239] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0240] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph K.

[0241] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph J.

[0242] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph I.

[0243] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph K.

[0244] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph J.

[0245] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph I.

[0246] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph K.

[0247] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph J.

[0248] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph I.

[0249] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, azithromycin administered according to paragraph V, and amikacin administered according to paragraph K.

[0250] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, azithromycin administered according to paragraph V, and amikacin administered according to paragraph J.

[0251] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, azithromycin administered according to paragraph V, and amikacin administered according to paragraph I.

[0252] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph K.

[0253] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0254] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0255] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph K.

[0256] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0257] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0258] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph P, azithromycin administered according to paragraph U, and amikacin administered according to paragraph K.

[0259] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0260] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0261] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph K.

[0262] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0263] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0264] V.xxix.) Eperborole & ethambutol & rifampicin & clarithromycin & amikacin

[0265] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0266] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0267] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph J.

[0268] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph I.

[0269] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0270] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph J.

[0271] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph I.

[0272] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0273] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph J.

[0274] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph P, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph I.

[0275] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0276] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph J.

[0277] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph I.

[0278] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph P, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0279] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0280] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph I.

[0281] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0282] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph O, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0283] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifampicin administered according to paragraph O, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph I.

[0284] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph K.

[0285] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0286] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph P, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph I.

[0287] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifampicin is administered according to paragraph O, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0288] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0289] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifampicin administered according to paragraph O, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph I.

[0290] V.xxx.) Eperborole & Ethambutol & Rifabutin & Azithromycin & Amikacin

[0291] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0292] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph K.

[0293] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph J.

[0294] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph I.

[0295] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph K.

[0296] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph J.

[0297] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph V, and amikacin is administered according to paragraph I.

[0298] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph V, and amikacin administered according to paragraph K.

[0299] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph V, and amikacin administered according to paragraph J.

[0300] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph V, and amikacin administered according to paragraph I.

[0301] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph V, and amikacin administered according to paragraph K.

[0302] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph V, and amikacin administered according to paragraph J.

[0303] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph V, and amikacin administered according to paragraph I.

[0304] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph K.

[0305] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0306] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0307] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph K.

[0308] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph J.

[0309] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, azithromycin is administered according to paragraph U, and amikacin is administered according to paragraph I.

[0310] In an exemplary embodiment, the dosage regimen comprises epaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph U, and amikacin administered according to paragraph K.

[0311] In an exemplary embodiment, the dosage regimen comprises epaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph U, and amikacin administered according to paragraph J.

[0312] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, azithromycin administered according to paragraph U, and amikacin administered according to paragraph I.

[0313] In an exemplary embodiment, the dosage regimen comprises epaborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph U, and amikacin administered according to paragraph K.

[0314] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph U, and amikacin administered according to paragraph J.

[0315] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, azithromycin administered according to paragraph U, and amikacin administered according to paragraph I.

[0316] V.xxxi.) Eperborole & ethambutol & rifabutin & clarithromycin & amikacin

[0317] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0318] In an exemplary embodiment, the dosage regimen comprises epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0319] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph J.

[0320] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph I.

[0321] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0322] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph J.

[0323] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph I.

[0324] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph S, and amikacin is administered according to paragraph K.

[0325] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph J.

[0326] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph I.

[0327] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph K.

[0328] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph J.

[0329] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph L, clarithromycin administered according to paragraph S, and amikacin administered according to paragraph I.

[0330] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0331] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph Y, rifabutin administered according to paragraph M, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0332] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph I.

[0333] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0334] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph J.

[0335] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph Y, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph I.

[0336] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0337] In an exemplary embodiment, the dosage regimen comprises eperborole, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol, or a hydrate, solvate, or pharmaceutically acceptable salt thereof, administered according to paragraph X, rifabutin administered according to paragraph M, clarithromycin administered according to paragraph R, and amikacin administered according to paragraph J.

[0338] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph M, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph I.

[0339] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph K.

[0340] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph J.

[0341] In an exemplary embodiment, the dosage regimen comprises eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof, administered at an oral dose of about 450 mg to about 550 mg, or about 490 mg to about 510 mg, or about 500 mg, or 500 mg per day, ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered according to paragraph X, rifabutin is administered according to paragraph L, clarithromycin is administered according to paragraph R, and amikacin is administered according to paragraph I.

[0342] V.xxxii.) Eperborole & ethambutol & rifampicin & azithromycin & streptomycin

[0343] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0344] V.xxxiii.) Eperborole & ethambutol & rifampicin & clarithromycin & streptomycin

[0345] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0346] V.xxxiv.) Eperborole & ethambutol & rifabutin & azithromycin & streptomycin

[0347] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, azithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0348] V.xxxv.) Eperborole & ethambutol & rifabutin & clarithromycin & streptomycin

[0349] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and streptomycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0350] V.xxxvi.) Eperborole & ethambutol & rifampicin & moxifloxacin & amikacin

[0351] In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method for achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising: administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifampicin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0352] V.xxxvii.) Eperborole & ethambutol & rifabutin & moxifloxacin & amikacin

[0353] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and intravenous amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole or a hydrate, solvate, or pharmaceutically acceptable salt thereof, ethambutol or a hydrate, solvate, or pharmaceutically acceptable salt thereof, rifabutin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, moxifloxacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, and inhaled amikacin or a hydrate, solvate, or pharmaceutically acceptable salt thereof, thereby achieving a positive therapeutic response.

[0354] Va). Nontuberculous mycobacterial (NTM) infections

[0355] In an exemplary embodiment, the nontuberculous mycobacteria in the infection are rapidly growing. In an exemplary embodiment, the nontuberculous mycobacteria in the infection are M. abscessus, M. arabiense, M. aromaticivorans, M. bacteremicum, M. barrassiae, M. bourgelatii, M. celeriflavum, M. chelonae, M. crocinum, M. fukienense ), M. hippocampi, M. insubricum, M. iranicum, M. litorale, M. llatzerense, M. monacense, M. pallens, M. rufum, M. rutilum, M. salmoniphilum, M. sediminis or Mycobacterium setense, or a combination thereof.

[0356] In an exemplary embodiment, the nontuberculous mycobacteria in the infection are slow growing. In an exemplary embodiment, the nontuberculous mycobacteria in the infection are Mycobacterium algericum, Mycobacterium alsiense, Mycobacterium aorsiense, Mycobacterium bouchedurhonense, Mycobacterium engbaekii, Mycobacterium europaeum, Mycobacterium fragae, Mycobacterium heraklionense, Mycobacterium intracellularis subspecies (M. indicus pranii), Korean Mycobacterium (M.koreense), Kumamoto Mycobacterium (M.kumamotonense), Xinglin Mycobacterium (M.kyorinense), Tumor-type Mycobacterium lepromatosis (M.lepromatosis), Flemish Mycobacterium (M.liflandii), Lombardy Mycobacterium (M.longobardum), Manten Mycobacterium (M.mantenii), Massa Mycobacterium (M.marseillense), Minnesota Mycobacterium (M.minnesotense), Nijmegen Mycobacterium (M.noviomagense), Paraffin Mycobacterium (M.paraffinicum), Paragordonae Mycobacterium (M.paragordonae), Parakorean Mycobacterium (M.parakoreense) , M. paraseoulense, M. paraterrae, M. riyadhense, M. senuense, M. seoulense, M. sherrisii, M. shigaense, M. shinjukuense, M. simulans, M. sinense, M. stomatepiae, M. timonense, M. vulneris, or M. yongonense, or a combination thereof.

[0357] In an exemplary embodiment, the nontuberculous mycobacteria in the infection are selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium gordonae, Mycobacterium kansasii, Mycobacterium mucogenicum, Mycobacterium peregrinum, and Mycobacterium xenopi. In an exemplary embodiment, the nontuberculous mycobacteria in the infection are selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium fortuitum complex, Mycobacterium gordonae, Mycobacterium kansasii, and Mycobacterium xenopi.

[0358] In an exemplary embodiment, the nontuberculous mycobacterium in the infection is the Mycobacterium avium complex. In an exemplary embodiment, the nontuberculous mycobacterium in the infection is Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium Marseillaise, Mycobacterium timonei, Mycobacterium estuary du Rhone, Mycobacterium colombiense, Mycobacterium wounds, or Mycobacterium chimaera. In an exemplary embodiment, the nontuberculous mycobacterium in the infection is Mycobacterium intracellulare. In an exemplary embodiment, the nontuberculous mycobacterium in the infection is Mycobacterium intracellulare subspecies (M.intracellulare subsp.intracellulare) or Mycobacterium intracellulare subspecies (M.intracellulare subsp.). In an exemplary embodiment, the nontuberculous mycobacterium in the infection is Mycobacterium avium.

[0359] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxiv.); V.xxv.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.); V.xxxii.); V.xxxiii.); V.xxxiv.); V.xxxv.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides compositions or methods for achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, eg, in section III) or III.a.).

[0360] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against an infection with Mycobacterium avium as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxiv.); V.xxv.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.); V.xxxii.); V.xxxiii.); V.xxxiv.); V.xxxv.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides compositions or methods for achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, eg, in section III) or III.a.).

[0361] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against an infection with Mycobacterium intracellulare as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxiv.); V.xxv.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.); V.xxxii.); V.xxxiii.); V.xxxiv.); V.xxxv.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides compositions or methods for achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, eg, in section III) or III.a.).

[0362] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against an infection with Mycobacterium kansasii as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides a composition or method of achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, e.g., in section III) or III.a.).

[0363] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against an infection with Mycobacterium kansasii as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides a composition or method of achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, e.g., in section III) or III.a.).

[0364] In an exemplary embodiment, the human also suffers from a disease that is cystic fibrosis, chronic obstructive pulmonary disease, or chronic thromboembolic pulmonary hypertension. In an exemplary embodiment, the human also suffers from the following diseases: interstitial lung disease, post-inflammatory pulmonary fibrosis, bronchiectasis, neoplastic disease, diabetes, bronchial asthma, hypothyroidism, mediastinal cysts, or rheumatoid arthritis. In an exemplary embodiment, the human also suffers from a disease that is interstitial lung disease, and the interstitial lung disease is idiopathic pulmonary fibrosis, sarcoidosis, or proteinosis. In an exemplary embodiment, the human also suffers from a neoplastic disease, and the neoplastic disease is myelofibrosis or lung cancer. In an exemplary embodiment, the human previously suffered from tuberculosis.

[0365] In an exemplary embodiment, the infection is in the lungs of a human. In an exemplary embodiment, the infection is in two or more organs in the body. In an exemplary embodiment, the infection is in a lymph node.

[0366] In an exemplary embodiment, the infection is untreated.In an exemplary embodiment, the infection is treatment refractory.

[0367] In another aspect, nontuberculous mycobacterium infection is part of a nontuberculous mycobacterium-related disease in a human subject. In an exemplary embodiment, the nontuberculous mycobacterium-related disease is nontuberculous mycobacterium-lung disease, disseminated nontuberculous mycobacterium disease or nontuberculous mycobacterium-related lymphadenitis. In an exemplary embodiment, the nontuberculous mycobacterium-related disease is Mycobacterium avium complex (MAC)-lung disease, disseminated Mycobacterium avium complex (MAC) disease and Mycobacterium avium complex (MAC)-related lymphadenitis. In an exemplary embodiment, the nontuberculous mycobacterium-related disease is nodular bronchiectasis. In an exemplary embodiment, the nontuberculous mycobacterium-related disease is fibrocavitary.

[0368] In an exemplary embodiment, the non-binding mycobacterium-associated disease is untreated. In an exemplary embodiment, the non-binding mycobacterium-associated disease is treatment refractory. In an exemplary embodiment, the non-binding mycobacterium-associated disease is treatment refractory Mycobacterium avium complex (MAC) lung disease. In an exemplary embodiment, the non-binding mycobacterium-associated disease is cavitary Mycobacterium avium complex (MAC) lung disease. In an exemplary embodiment, the non-tuberculous mycobacterium-associated disease is nodular bronchiectasis Mycobacterium avium complex (MAC) lung disease.

[0369] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nodular bronchiectasis Mycobacterium avium complex (MAC) lung disease as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides a composition or method of achieving a positive therapeutic response against a Mycobacterium avium complex infection as described herein, e.g., in section III) or III.a.).

[0370] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response for Mycobacterium avium complex (MAC) lung disease as described herein, e.g., in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xvi.); V.xxiv.); V.xxv.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.); V.xxxii.); and V.xxxiii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response for Mycobacterium avium complex (MAC) lung disease as described herein, e.g., in section V.xv.) or V.xvii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides a composition or method for achieving a positive therapeutic response as described herein against an infection with Mycobacterium avium complex as described herein, eg, in section III) or III.a.).

[0371] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response for treating refractory Mycobacterium avium complex (MAC) lung disease as described herein, e.g., in Section V below: i.); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxiv.); V.xxv.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.); V.xxxii.); and V.xxxiii.), thereby achieving a positive therapeutic response. In an exemplary embodiment, the invention provides compositions or methods for achieving a positive therapeutic response against an infection with Mycobacterium avium complex as described herein, eg, in section III) or III.a.).

[0372] In an exemplary embodiment, the disease is treated by oral administration of a compound of the invention. In an exemplary embodiment, the disease is treated by oral administration of eperborole.

[0373] Vb). Evaluation of positive treatment response

[0374] In an exemplary embodiment, a positive therapeutic response can be assessed by the assays or tools described herein.

[0375] In an exemplary embodiment, prior to administration, the human subject is assessed for infection markers to obtain a baseline assessment; after the first administration, the human subject is assessed for infection markers to obtain a response assessment, the baseline assessment and the response assessment are compared, and a positive therapeutic response is achieved when the response assessment is an improvement over the baseline assessment. Multiple response assessments can be performed during administration. A positive therapeutic response is achieved if a subsequent response assessment is an improvement over a previous response assessment or baseline assessment.

[0376] In an exemplary embodiment, before applying the dosage regimen described herein, the infection marker of the human subject is assessed, wherein the infection marker thus obtains a baseline assessment; after the first administration of the dosage regimen, the infection marker of the human subject is assessed to obtain a reaction assessment, compare the baseline assessment and the reaction assessment, and when the reaction assessment is an improvement relative to the baseline assessment, a positive therapeutic response is achieved. In an exemplary embodiment, the infection marker is assessed within 2 days, or within 3 days, or within 4 days, or within 5 days, or within 6 days, or within 7 days after the dosage regimen occurs. In an exemplary embodiment, the infection marker is assessed within 2 days, or within 3 days, or within 4 days, or within 5 days, or within 6 days, or within 7 days after the occurrence of the dosage regimen as described in paragraph A. In some methods, the dosage regimen occurs multiple times. In some methods, the dosage regimen occurs as described in paragraph B. In the case of multiple occurrences of the dosage regimen, the infection marker of the human subject can be assessed within 2 days, or within 3 days, or within 4 days, or within 5 days, or within 6 days, or within 7 days after the occurrence of the dosage regimen as described in paragraph A ends. A positive treatment response is achieved if the subsequent response assessment is an improvement relative to the previous response assessment or the baseline assessment.

[0377] In an exemplary embodiment, a positive therapeutic response to an NTM infection as described herein can be assessed by assessing one or more properties of the NTM infection in a patient prior to administering a composition as described herein, thereby obtaining a baseline assessment or evaluation. After the first administration of at least one of the dosage regimens described herein, the NTM infection characteristics are again assessed or evaluated to obtain a response assessment. By comparing the baseline assessment and the response assessment, it can be determined whether a positive therapeutic response has been achieved. If the response assessment is an improvement over the baseline assessment, a positive therapeutic response for the NTM infection is achieved. In an exemplary embodiment, more than one response assessment is performed at different times during the course of treatment (during one or more times of implementing the dosage regimen). In an exemplary embodiment, NTM infection is assessed by assessing one or more infection markers in a human subject.

[0378] In an exemplary embodiment, a positive treatment response can be assessed by quantitative colony counting. In an exemplary embodiment, a positive treatment response can be assessed by quantitative colony scoring. In an exemplary embodiment, a positive treatment response can be assessed by radiographic analysis.

[0379] Vb)i.) Quantitative colony count

[0380] Bacterial quantification can be performed by colony counts on solid agar according to standard methods known in the art. An example of this is described in Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015; 192 (6): 754-760 by Griffith et al. In Am J Respir Crit Care Med. 192 (6): 754-760, colony counts predict symptom and radiological improvement. As described in Griffith, quantitative colony counts can be obtained from respiratory samples (e.g., sputum samples, such as expectorated sputum samples or induced sputum samples) obtained from patients. Induced sputum samples can be obtained from human subjects by, for example, administering a hypertonic saline solution (e.g., 7% saline) to a human subject by a nebulizer. Sputum samples can be processed according to methods such as decontamination, fluorescent dye microscopy, solid medium culture on a double plate of Middlebrook 7H10 agar with and without antibiotics, and broth culture (BACTEC 960 [Becton Dickinson, Sparks, MD] or ESP [TREK Diagnostic Systems, Cleveland, OH]), as described by Wallace et al., Initial Clarithromycin monotherapy for Mycobacterium avium-intracellularecomplex lung disease. Am J Respir Crit Care Med 1994; 149: 1335-1341; Wallace et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first50patients. Am J Respir Crit Care Med 1996; 153: 1766-1772. For example, MAC isolates can be identified using AccuProbe (Hologic-GenProbe, San Diego, CA).

[0381] The microbiological evaluation of sputum samples can include quantitative colony count evaluation. In an exemplary embodiment, a quantitative colony count lower than the previous evaluation in a subsequent evaluation is a positive treatment response. In an exemplary embodiment, a lower quantitative colony count relative to a baseline evaluation in a reaction evaluation is a positive treatment response. In an exemplary embodiment, a quantitative colony count lower than the previous reaction evaluation in a subsequent reaction evaluation is a positive treatment response. In an exemplary embodiment, a quantitative colony count lower than the first reaction evaluation in a second (or third or fourth, etc.) reaction evaluation is a positive treatment response. In an exemplary embodiment, a lower number of colony counts relative to the second reaction evaluation in a third (or fourth or fifth, etc.) reaction evaluation is a positive treatment response. In an exemplary embodiment, a quantitative colony count of about 1%-about 99% lower in a subsequent evaluation than in a previous evaluation is a positive treatment response. In an exemplary embodiment, the quantitative colony count in a subsequent assessment is about 1% to about 5%, or about 4% to about 9%, or about 8% to about 13%, or about 12% to about 17%, or about 16% to about 21%, or about 20% to about 25%, or about 24% to about 29%, or about 28% to about 33%, or about 32% to about 37%, or about 36% to about 41%, or about 40% to about 45%, or about 44% to about 49%, or about 50% to about 51%, or about 52% to about 53%, or about 54% to about 55%, or about 56% to about 57%, or about 58% to about 59%, or about 60% to about 61%, or about 62% to about 63%, or about 64% to about 65%, or about 66% to about 67%, or about 68% to about 69%, or about 70% to about 71%, or about 72% to about 73%, or about 74% to about 75%, or about 76% to about 77%, or about 78% to about 79%, or about 80% to about 81%, or about 82% to about 83%, or about 84% to about 85%, or about 86% to about 87%, or about 88% to about 89%, or about 90% to about 91%, or about 91% to about 92%, or about 93% to about 94%, or about 95% to about 96% About 48% to about 53%, or about 52% to about 57%, or about 56% to about 61%, or about 60% to about 65%, or about 64% to about 69%, or about 68% to about 73%, or about 72% to about 77%, or about 76% to about 81%, or about 80% to about 85%, or about 84% to about 89%, or about 88% to about 93%, or about 92% to about 97%, or about 96% to about 100%, or a combination of one or more thereof, is a positive therapeutic response.

[0382] In an exemplary embodiment, a quantitative colony count in a subsequent assessment that is about 5% to about 25%, or about 5% to about 30%, or about 5% to about 35%, or about 5% to about 40%, or about 5% to about 45%, or about 5% to about 50%, or about 5% to about 55%, or about 5% to about 60%, or about 5% to about 65%, or about 5% to about 70%, or about 5% to about 75%, or about 5% to about 80%, or about 5% to about 85%, or about 5% to about 90%, or about 5% to about 95%, or about 5% to about 99%, or about 5% to about 99.2%, or about 5% to about 99.5%, or about 5% to about 99.7%, or about 5% to about 99.9%, or about 5% to 100% lower than the quantitative colony count in the previous assessment is a positive therapeutic response.

[0383] In an exemplary embodiment, a quantitative colony count in a subsequent assessment that is about 10% to about 25%, or about 10% to about 30%, or about 10% to about 35%, or about 10% to about 40%, or about 10% to about 45%, or about 10% to about 50%, or about 10% to about 55%, or about 10% to about 60%, or about 10% to about 65%, or about 10% to about 70%, or about 10% to about 75%, or about 10% to about 80%, or about 10% to about 85% or less, or about 10% to about 90%, or about 10% to about 95%, or about 10% to about 99%, or about 10% to about 99.2%, or about 10% to about 99.5%, or about 10% to about 99.7%, or about 10% to about 99.9%, or about 10% to 100% lower than the quantitative colony count in the previous assessment is a positive therapeutic response.

[0384] In an exemplary embodiment, a quantitative colony count in a subsequent assessment that is about 15% to about 25%, or about 15% to about 30%, or about 15% to about 35%, or about 15% to about 40%, or about 15% to about 45%, or about 15% to about 50%, or about 15% to about 55%, or about 15% to about 60%, or about 15% to about 65%, or about 15% to about 70%, or about 15% to about 75%, or about 15% to about 80%, or about 15% to about 85%, or about 15% to about 90%, or about 15% to about 95%, or about 15% to about 99%, or about 15% to about 99.2%, or about 15% to about 99.5%, or about 15% to about 99.7%, or about 15% to about 99.9%, or about 15% to 100% lower than the quantitative colony count in the previous assessment is a positive therapeutic response.

[0385] In an exemplary embodiment, a quantitative colony count in a subsequent assessment of about 20% to about 30%, or about 20% to about 35%, or about 20% to about 40%, or about 20% to about 45%, or about 20% to about 50%, or about 20% to about 55%, or about 20% to about 60%, or about 20% to about 65%, or about 20% to about 70%, or about 20% to about 75%, or about 20% to about 80%, or about 20% to about 85%, or about 20% to about 90%, or about 20% to about 95%, or about 20% to about 99%, or about 20% to about 99.2%, or about 20% to about 99.5%, or about 20% to about 99.7%, or about 20% to about 99.9%, or about 20% to 100% more than the quantitative colony count in the previous assessment is a positive therapeutic response.

[0386] In an exemplary embodiment, prior to administering the dosing regimen, the human subject is assessed for a marker of infection, wherein the marker of infection is a quantitative colony count, thereby obtaining a baseline assessment; after the first administration of epaborole, the human subject is assessed for a marker of infection, thereby obtaining a response assessment, the baseline assessment and the response assessment are compared, and a positive therapeutic response is achieved when the response assessment is an improvement relative to the baseline assessment.

[0387] In an exemplary embodiment, a positive therapeutic response to NTM infection can be assessed by assessing one or more properties of the NTM infection in a patient prior to administering the compositions described herein, thereby obtaining a baseline assessment or evaluation. After the first administration of at least one of the compositions described herein, the properties of the NTM infection are again assessed or evaluated, thereby obtaining a response assessment. By comparing the baseline assessment and the response assessment, it can be determined whether a positive therapeutic response has been achieved. If the response assessment is an improvement over the baseline assessment, a positive therapeutic response to the NTM infection is achieved. In an exemplary embodiment, more than one response assessment is performed at different times during the course of treatment (during one or more times of implementing the dosage regimen). In an exemplary embodiment, NTM infection is assessed by assessing one or more infection markers in a human subject. In an exemplary embodiment, the infection marker is a quantitative colony count.

[0388] Quantitative colony scoring

[0389] Microbiological evaluation of sputum samples may include evaluation of quantitative colony scores. The classification score, i.e., the quantitative colony score, may be assigned as reported in Griffith et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015; 192(6): 754-760. In an exemplary embodiment, a negative culture shows no mycobacterial growth and can be assigned a quantitative colony score of zero; a positive culture growing only in broth medium can be assigned a quantitative colony score of 1; a positive growth on solid medium with between 0 and 49 countable colonies can be assigned a quantitative colony score of 2; a positive growth on solid medium with between 50 and 99 countable colonies can be assigned a quantitative colony score of 3; a positive growth on solid medium with between 100 and 199 countable colonies can be assigned a quantitative colony score of 4; a positive growth on solid medium with between 200 and 299 countable colonies can be assigned a quantitative colony score of 5; a positive growth on solid medium with countable colonies of 300 and above can be assigned a quantitative colony score of 6. Human subjects who show no mycobacterial growth (score of "0") in three or more consecutive cultures over a minimum of 3 months are labeled "converters".

[0390] In an exemplary embodiment, a quantitative colony score lower in a subsequent assessment than in a previous assessment is a positive therapeutic response. In an exemplary embodiment, a lower quantitative colony score in a response assessment relative to a baseline assessment is a positive therapeutic response. In an exemplary embodiment, a quantitative colony score lower in a subsequent response assessment than in a previous response assessment is a positive therapeutic response. In an exemplary embodiment, a quantitative colony score lower than the first response assessment in the second (or third or fourth, etc.) response assessment is a positive therapeutic response. In an exemplary embodiment, a quantitative colony score lower than the second response assessment in the third (or fourth or fifth, etc.) response assessment is a positive therapeutic response. In an exemplary embodiment, a positive therapeutic response is when the quantitative colony score in the subsequent assessment is 1 lower than in the previous assessment. In an exemplary embodiment, a positive therapeutic response is when the quantitative colony score in the subsequent assessment is 1 or more lower than in the previous assessment. In an exemplary embodiment, a positive therapeutic response is when the quantitative colony score in the subsequent assessment is 2 lower than in the previous assessment. In an exemplary embodiment, a positive therapeutic response is when the quantitative colony score in the subsequent assessment is 2 or more lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 3 lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 3 or more lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 4 lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 4 or more lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 6 lower than in the previous assessment. In an exemplary embodiment, a positive treatment response is when the quantitative colony score in the subsequent assessment is 6 or more lower than in the previous assessment.

[0391] In an exemplary embodiment, the quantitative culture score is assessed prior to the first administration of iperborole. In an exemplary embodiment, the quantitative culture score baseline assessment is performed 56 days to 1 day prior to the first administration of iperborole. In an exemplary embodiment, the quantitative culture score baseline assessment is taken one day prior to the first administration of iperborole. In an exemplary embodiment, the quantitative culture score response assessment is performed after the first administration of iperborole. In an exemplary embodiment, the quantitative culture score response assessment is performed about 21 days to about 35 days after the first administration of iperborole. In an exemplary embodiment, a positive therapeutic response is achieved when the quantitative culture score in the response assessment is lower than at least one or more categorical scores of the quantitative culture score in the baseline assessment. In an exemplary embodiment, a positive therapeutic response is achieved when the quantitative culture score in the response assessment is 1 or 2 or 3 or 4 or 5 or 6 lower than the quantitative culture score in the baseline assessment. In an exemplary embodiment, a positive therapeutic response is achieved when the quantitative culture score in the response assessment is 1 or 2 lower than the quantitative culture score in the baseline assessment. In an exemplary embodiment, a positive therapeutic response is achieved when the quantitative culture score in the response assessment is 1 or 2 lower than the quantitative culture score in the baseline assessment. In an exemplary embodiment, a positive therapeutic response is achieved when the quantitative culture score in the response assessment is 1 lower than the quantitative culture score in the baseline assessment. In an exemplary embodiment, a positive treatment response is achieved when the quantitative culture score in the response assessment is at least 1 lower than the quantitative culture score in the baseline assessment.

[0392] Radiographic evaluation

[0393] In an exemplary embodiment, a positive treatment response is an improvement in a radiographic assessment, such as a chest radiograph or a computed tomography (CT) scan of the chest or a high-resolution computed tomography (CT) scan of the chest. Such assessments are known in the art and are described, for example, in Griffith et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015; 192(6): 754-760.

[0394] In an exemplary embodiment, a chest radiograph (CXR) and a high-resolution computed tomography (HRCT) chest scan may be performed prior to the start of the administration regimen described herein, and then at intervals of 1-2 months for chest radiographs and 6 months for chest CT scans, with more frequent chest CT scans determined by the medical professional / radiologist. In an exemplary embodiment, the baseline and response chest radiographs and / or CT scans may be reviewed by a medical professional caring for the patient and a radiologist experienced in reviewing radiographs from NTM patients (such as MAC human subjects with nodular / bronchiectatic disease). In an exemplary embodiment, a second radiologist may review the radiographs of the human subject. In an exemplary embodiment, the radiographs may be classified as improved (score, 1), no change (score, 0), or worse (score, -1) when compared to previous radiographs. In an exemplary embodiment, specific score assignments are based on a global or overall impression of the radiographic appearance. In an exemplary embodiment, the radiographs may have a "mixed" response compared to previous radiographic studies, with some areas improving and some areas increasing in density. In one exemplary embodiment, discrepancies between the radiologist's and clinician's interpretations of radiographs may be resolved by a second radiologist who is blinded to the human subject's clinical status.

[0395] In an exemplary embodiment, a higher radiographic assessment score in a subsequent assessment compared to a previous assessment is a positive treatment response. In an exemplary embodiment, a higher radiographic assessment score in a response assessment compared to a baseline assessment is a positive treatment response. In an exemplary embodiment, a higher radiographic assessment score in a subsequent response assessment relative to a previous response assessment is a positive treatment response. In an exemplary embodiment, a higher radiographic assessment score in a second (or third or fourth, etc.) response assessment compared to a first response assessment is a positive treatment response. In an exemplary embodiment, a higher radiographic assessment score in a third (or fourth or fifth, etc.) response assessment compared to a second response assessment is a positive treatment response.

[0396] Continuous administration of Vc

[0397] In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue until a positive therapeutic response is achieved. In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue until a positive therapeutic response is achieved. In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue when there is a positive therapeutic response. In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue as long as there is a positive therapeutic response. In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue for about 6 months, or about 7 months, or about 8 months, or about 9 months, or about 10 months. In some embodiments, administration as described herein, for example, in part III or IIIa or Vi)-V.xxxvii.), can continue for about 11 months, or about 12 months, or about 13 months, or about 14 months, or about 15 months, or about 16 months. In some embodiments, administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, can last for about 16 months, or about 17 months, or about 18 months, or about 19 months, or about 20 months, or about 21 months. In some embodiments, administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, can last for about 21 months, or about 22 months, or about 23 months, or about 24 months, or about 25 months, or about 26 months. In some embodiments, administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, can last for about 26 months, or about 27 months, or about 28 months, or about 29 months, or about 30 months. In some embodiments, administration as described herein, for example in part III or IIIa or Vi)-V.xxxvii.), can last for at least about 6 months, or about 7 months, or about 8 months, or about 9 months, or about 10 months. In some embodiments, administration as described herein, for example in part III or IIIa or Vi)-V.xxxvii.), can last for at least about 11 months, or about 12 months, or about 13 months, or about 14 months, or about 15 months, or about 16 months. In some embodiments, administration as described herein, for example in part III or IIIa or Vi)-V.xxxvii.), can last for at least about 16 months, or about 17 months, or about 18 months, or about 19 months, or about 20 months, or about 21 months.In some embodiments, administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) sections, can continue for at least about 21 months, or about 22 months, or about 23 months, or about 24 months, or about 25 months, or about 26 months. In some embodiments, administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) sections, can continue for at least about 26 months, or about 27 months, or about 28 months, or about 29 months, or about 30 months.

[0398] In some embodiments, the administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, ends after the positive therapeutic response no longer exists. In some embodiments, the administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, ends at about 6 months, or about 7 months, or about 8 months, or about 9 months, or about 10 months. In some embodiments, the administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, ends at about 11 months, or about 12 months, or about 13 months, or about 14 months, or about 15 months, or about 16 months. In some embodiments, the administration as described herein, for example in III or IIIa or Vi)-V.xxxvii.) parts, ends at about 16 months, or about 17 months, or about 18 months, or about 19 months, or about 20 months, or about 21 months. In some embodiments, administration as described herein, e.g., in parts III or IIIa or Vi)-V.xxxvii.), ends at about 21 months, or about 22 months, or about 23 months, or about 24 months, or about 25 months, or about 26 months. In some embodiments, administration as described herein, e.g., in parts III or IIIa or Vi)-V.xxxvii.), ends at about 26 months, or about 27 months, or about 28 months, or about 29 months, or about 30 months.

[0399] Vd) Dosage regimen occurrence / repetition

[0400] In some embodiments, the dosage regimens described herein above, e.g., in sections Vi)-V.xxxvii., have the parameters as described in this section.

[0401] Paragraph A: In an exemplary embodiment, the dosage regimen lasts about 21-about 35 days. In an exemplary embodiment, the dosage regimen lasts about 22-about 34 days. In an exemplary embodiment, the dosage regimen lasts about 23-about 33 days. In an exemplary embodiment, the dosage regimen lasts about 24-about 32 days. In an exemplary embodiment, the dosage regimen lasts about 25-about 31 days. In an exemplary embodiment, the dosage regimen lasts about 26-about 30 days. In an exemplary embodiment, the dosage regimen lasts about 27-about 29 days. In an exemplary embodiment, the dosage regimen lasts about 28 days. In an exemplary embodiment, the dosage regimen lasts 28 days.

[0402] Paragraph B: In an exemplary embodiment, the dosage regimen occurs 1 time. In an exemplary embodiment, the dosage regimen occurs 2 times. In an exemplary embodiment, the dosage regimen occurs 3 times. In an exemplary embodiment, the dosage regimen occurs 4 times. In an exemplary embodiment, the dosage regimen occurs 5 times. In an exemplary embodiment, the dosage regimen occurs 6 times. In an exemplary embodiment, the dosage regimen occurs 7 times. In an exemplary embodiment, the dosage regimen occurs 8 times. In an exemplary embodiment, the dosage regimen occurs 9 times. In an exemplary embodiment, the dosage regimen occurs 10 times. In an exemplary embodiment, the dosage regimen occurs 11 times. In an exemplary embodiment, the dosage regimen occurs 12 times. In an exemplary embodiment, the dosage regimen occurs 13 times. In an exemplary embodiment, the dosage regimen occurs 14 times. In an exemplary embodiment, the dosage regimen occurs 15 times. In an exemplary embodiment, the dosage regimen occurs 16 times. In an exemplary embodiment, the dosage regimen occurs 17 times. In an exemplary embodiment, the dosage regimen occurs 18 times. In an exemplary embodiment, the dosage regimen occurs 19 times. In an exemplary embodiment, the dosage regimen occurs 20 times. In an exemplary embodiment, the dosage regimen occurs 21 times. In an exemplary embodiment, the dosage regimen occurs 22 times. In an exemplary embodiment, the dosage regimen occurs 23 times. In an exemplary embodiment, the dosage regimen occurs 24 times. In an exemplary embodiment, the dosage regimen occurs 25 times. In an exemplary embodiment, the dosage regimen occurs 26 times. In an exemplary embodiment, the dosage regimen occurs 27 times. In an exemplary embodiment, the dosage regimen occurs 28 times. In an exemplary embodiment, the dosage regimen occurs 29 times. In an exemplary embodiment, the dosage regimen occurs 30 times. In an exemplary embodiment, the dosage regimen occurs 31 times. In an exemplary embodiment, the dosage regimen is repeated until a positive therapeutic response is achieved. In an exemplary embodiment, the dosage regimen is continued until a positive therapeutic response is achieved. In an exemplary embodiment, the dosage regimen is repeated as long as there is a positive response. In an exemplary embodiment, the dosage regimen is continued as long as there is a positive therapeutic response. In an exemplary embodiment, the dosage regimen is administered to a human subject as long as there is a positive dose response.

[0403] Paragraph C: In an exemplary embodiment, an oral dose of ipeborole is administered once every about 20 hours to about 28 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 21 hours to about 27 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 22 hours to about 26 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 23 hours to about 25 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 24 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every 24 hours.

[0404] Paragraph D : In an exemplary embodiment, an oral dose of ipeborole is administered once every about 44 hours to about 52 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 45 hours to about 51 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 46 hours to about 50 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every about 47 hours to about 49 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once about every 48 hours. In an exemplary embodiment, an oral dose of ipeborole is administered once every 48 hours.

[0405] Paragraph E:In an exemplary embodiment, the oral dose of eperborole is about 200 mg to about 1100 mg. In an exemplary embodiment, the oral dose of eperborole is about 200 mg to about 300 mg. In an exemplary embodiment, the oral dose of eperborole is about 225 mg to about 275 mg. In an exemplary embodiment, the oral dose of eperborole is about 240 mg to about 260 mg. In an exemplary embodiment, the oral dose of eperborole is about 250 mg. In an exemplary embodiment, the oral dose of eperborole is 250 mg. In an exemplary embodiment, the oral dose of eperborole is about 400 mg to about 600 mg. In an exemplary embodiment, the oral dose of eperborole is about 425 mg to about 575 mg. In an exemplary embodiment, the oral dose of eperborole is about 450 mg to about 550 mg. In an exemplary embodiment, the oral dose of eperborole is about 475 mg to about 525 mg. In an exemplary embodiment, the oral dose of eperborole is about 490 mg to about 510 mg. In an exemplary embodiment, the oral dose of eperborole is about 500 mg. In an exemplary embodiment, the oral dose of eperborole is 500 mg. In an exemplary embodiment, the oral dose of eperborole is about 650 mg to about 850 mg. In an exemplary embodiment, the oral dose of eperborole is about 675 mg to about 825 mg. In an exemplary embodiment, the oral dose of eperborole is about 700 mg to about 800 mg. In an exemplary embodiment, the oral dose of eperborole is about 725 mg to about 775 mg. In an exemplary embodiment, the oral dose of eperborole is about 750 mg. In an exemplary embodiment, the oral dose of eperborole is 750 mg. In an exemplary embodiment, the oral dose of eperborole is about 900 mg to about 1100 mg. In an exemplary embodiment, the oral dose of eperborole is about 925 mg to about 1075 mg. In an exemplary embodiment, the oral dose of eperborole is about 950 mg to about 1050 mg. In an exemplary embodiment, the oral dose of eperborole is about 975 mg to about 1025 mg. In an exemplary embodiment, the oral dose of eperborole is about 1000 mg. In an exemplary embodiment, the oral dose of eperborole is 1000 mg.

[0406] In an exemplary embodiment, the oral dose of ipeborole is about 250 mg and is administered in one about 250 mg unit dosage form. In an exemplary embodiment, the oral dose of ipeborole is about 500 mg and is administered in two about 250 mg unit dosage forms. In an exemplary embodiment, the oral dose of ipeborole is about 500 mg and is administered in one about 500 mg unit dosage form. In an exemplary embodiment, the oral dose of ipeborole is 250 mg and is administered in one 250 mg unit dosage form. In an exemplary embodiment, the oral dose of ipeborole is 500 mg and is administered in two 250 mg unit dosage forms. In an exemplary embodiment, the oral dose of ipeborole is 500 mg and is administered in one 500 mg unit dosage form.

[0407] In an exemplary embodiment, the oral dosage of eperborole is a tablet. In an exemplary embodiment, the oral dosage of eperborole is a pill. In an exemplary embodiment, the oral dosage of eperborole is a capsule.

[0408] In an exemplary embodiment, the oral dose of eperborole is 250 mg and is administered in one 250 mg tablet. In an exemplary embodiment, the oral dose of eperborole is 500 mg and is administered in two 250 mg tablets. In an exemplary embodiment, the oral dose of eperborole is 500 mg and is administered in one 500 mg unit dosage form.

[0409] A medical professional with ordinary skill in the art can readily determine and prescribe the effective amount of the oral composition required. For example, a clinician can start the dosage of the drug used in the eperborole composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.

[0410] Dosage regimens are adjusted to provide the optimal desired response (e.g., therapeutic response). Dosage unit form as used herein refers to physically discrete units suitable as unit dosages for subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.

[0411] The specifications for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of individual sensitivities.

[0412] Ve). Specific dosage regimen implementation plan

[0413] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dosage of epaborole as described in paragraph E, administered on the first day of the dosage regimen, and administering the oral dosage as described in paragraph C, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dosage of epaborole of about 240 mg to about 260 mg, administered on the first day of the dosage regimen, and administering the oral dosage as described in paragraph C, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and wherein the oral dose is administered as described in paragraph C, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 725 mg to about 775 mg, administered on the first day of the dosage regimen, and wherein the oral dose is administered as described in paragraph C, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 1075 mg to about 1125 mg, administered on the first day of the dosage regimen, and wherein the oral dose is administered as described in paragraph C, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. For any embodiment in this paragraph, the oral dose is administered with food. For any embodiment in this paragraph, the oral dose is in a fasting state.

[0414] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole as described in paragraph E, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph D, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 240 mg to about 260 mg, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph D, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph D, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 725 mg to about 775 mg, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph D, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment an oral dose of ipeborole of about 1075 mg to about 1125 mg, administered on day 1 of the dose regimen, and administering the oral dose as described in paragraph D, wherein the dose regimen is as described in paragraph A, and wherein the dose regimen occurs as described in paragraph B. For any of the embodiments in this paragraph, the oral dose is administered with food. For any of the embodiments in this paragraph, the oral dose is in a fasting state.

[0415] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole as described in paragraph E, administered on the first day of the dosage regimen, and the oral dose is administered as described in paragraph C or paragraph D, wherein the dosage regimen is as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B.

[0416] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and the oral dose is administered as described in paragraph C, wherein the dosage regimen lasts for about 26 to about 30 days, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and the oral dose is administered as described in paragraph D, wherein the dosage regimen lasts for about 26 to about 30 days, and wherein the dosage regimen occurs as described in paragraph B.

[0417] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and the oral dose is administered as described in paragraph C, wherein the dosage regimen continues for about 28 days, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment epaborole, wherein the dosage regimen comprises: an oral dose of epaborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and the oral dose is administered as described in paragraph D, wherein the dosage regimen continues for about 28 days, and wherein the dosage regimen occurs as described in paragraph B.

[0418] In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment an iperborole dosage regimen comprising: an oral dose of iperborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph C, wherein the dosage regimen lasts for about 28 days, and the dosage regimen occurs 4-20 times or 12-17 times. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment an iperborole dosage regimen comprising: an oral dose of iperborole of about 475 mg to about 525 mg, administered on the first day of the dosage regimen, and administering the oral dose as described in paragraph D, wherein the dosage regimen lasts for about 28 days, and wherein the dosage regimen occurs 4-20 times or 12-17 times. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response for a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dose regimen comprising: an oral dose of about 475 mg to about 525 mg of ipaborole, administered on the first day of the dose regimen, and administering the oral dose as described in paragraph C, wherein the dose regimen continues for about 28 days, and the dose regimen occurs as long as there is a positive therapeutic response. In an exemplary embodiment, the present invention provides a method of achieving a positive therapeutic response for a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment a dose regimen comprising: an oral dose of about 475 mg to about 525 mg of ipaborole, administered on the first day of the dose regimen, and administering the oral dose as described in paragraph D, wherein the dose regimen continues for about 28 days, and wherein the dose regimen occurs as long as there is a positive therapeutic response. For any of the embodiments in this paragraph, the oral dose is administered with food. For any of the embodiments in this paragraph, the oral dose is in a fasting state.

[0419] In an exemplary embodiment, the present invention provides a method for achieving a positive treatment response for nontuberculous mycobacterium (NTM) infection, comprising administering ipaborol to a human subject who needs to be treated with the standard of care for NTM infection. In an exemplary embodiment, the human subject has been administered at least one previous NTM treatment that is not ipaborol, wherein the human subject has been administered at least two previous NTM treatments, neither of which is ipaborol. In an exemplary embodiment, for at least 6 of the last 12 months prior to the first dose of the dosing regimen, the previous NTM treatment was selected from at least 2 antimycobacterial agents according to current international treatment guidelines. In an exemplary embodiment, the previous NTM treatment is selected from clarithromycin, azithromycin, ethambutol, rifampicin, rifabutin, amikacin, bedaquiline, clofazimine, linezolid and fluoroquinolone. In an exemplary embodiment, the method also includes administering an optimized background regimen (OBR) treatment to the human subject. In an exemplary embodiment, the optimized background regimen (OBR) therapy is at least 2 antimycobacterial agents according to current American Thoracic Society (ATS) / European Respiratory Society (ERS) / European Society of Clinical Microbiology and Infectious Diseases (ESCMID) / Infectious Diseases Society of America (IDSA) treatment guidelines.

[0420] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need thereof according to a dosing regimen described herein, wherein the dosing regimen has a duration as described in paragraph A, and wherein the dosing regimen is carried out as described in paragraph B.

[0421] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.), wherein the dosage regimen has a duration as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B.

[0422] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv); V.vi.); V.vii.); V.viii.); V.ix.); Vx); V.xi.); V.xii.); V.xiii.); V.xiv.); V.xv.); V.xvi.); V.xvii.); V.xxviii.); V.xxix.); V.xxx.); V.xxxi.), wherein the dosage regimen has a duration of about 27 to about 29 days, and wherein the dosage regimen occurs as described in paragraph B.

[0423] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv), wherein the dosage regimen has a duration as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vi); V.ii.); V.iii.); V.iv.); Vv), wherein the dosage regimen has a duration of about 27 to about 29 days, and wherein the dosage regimen occurs as described in paragraph B.

[0424] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vx); V.xi.); xii.); V.xiii.), wherein the dosage regimen has a duration as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: Vx); V.xi.); V.xii.); V.xiii.), wherein the dosage regimen has a duration of about 27 to about 29 days, and wherein the dosage regimen occurs as described in paragraph B.

[0425] In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: V.xxviii.), V.xxix.), V.xxx.), and V.xxxi.), wherein the dosage regimen has a duration as described in paragraph A, and wherein the dosage regimen occurs as described in paragraph B. In an exemplary embodiment, the invention provides a method of achieving a positive therapeutic response against a nontuberculous mycobacterium (NTM) infection, comprising administering to a human subject in need of treatment according to a dosage regimen as described in the following sections: V.xxviii.), V.xxix.), V.xxx.), and V.xxxi.), wherein the dosage regimen has a duration of about 27 to about 29 days, and wherein the dosage regimen occurs as described in paragraph B.

[0426] VI. Selection of Human Subjects

[0427] In an exemplary embodiment, the methods described herein can be applied to human subjects having one or more selection and / or elimination criteria as described herein. In an exemplary embodiment, the methods described herein can be applied to human subjects having one or more criteria described in Section VI. In an exemplary embodiment, the methods described herein can be applied to human subjects having one or more selection criteria as described herein. In an exemplary embodiment, the methods described herein can be applied to human subjects having one or more elimination criteria as described herein.

[0428] The human subject can be selected according to the criteria described herein. In an exemplary embodiment, the human subject is male. In an exemplary embodiment, the human subject is female. In an exemplary embodiment, the human subject is 18 years old or older. In an exemplary embodiment, the age of the human subject is between 18 and 100 years old. In an exemplary embodiment, the age of the human subject is between 18 and 80 years old. In an exemplary embodiment, the age of the human subject is between 45 and 90 years old. In an exemplary embodiment, the age of the human subject is between 45 and 80 years old. In an exemplary embodiment, the age of the human subject is between 50 and 90 years old. In an exemplary embodiment, the age of the human subject is between 55 and 85 years old. In an exemplary embodiment, the age of the human subject is between 60 and 80 years old. In an exemplary embodiment, the age of the human subject is between 60 and 70 years old.

[0429] In an exemplary embodiment, the human subject is diagnosed with NTM infection. In an exemplary embodiment, the human subject has a diagnosis of a refractory NTM infection. In an exemplary embodiment, the human subject has a diagnosis of a refractory NTM disease. In an exemplary embodiment, the human subject has a diagnosis of a refractory NTM lung disease. In an exemplary embodiment, the human subject has a diagnosis of a refractory MAC infection. In an exemplary embodiment, the human subject has a diagnosis of a refractory MAC disease. In an exemplary embodiment, the human subject has a diagnosis of a refractory MAC lung disease. In an exemplary embodiment, the human subject has experienced progression of an NTM infection. In an exemplary embodiment, the human subject is able to provide written informed consent. In an exemplary embodiment, the human subject has a diagnosis of a refractory MAC lung disease consisting of the following microbiological criteria: - A pre-study MAC positive respiratory specimen. This specimen may be collected within 6 months prior to screening based on documentation in the patient's medical record. The respiratory sample can be a cough or induced sputum sample or deep bronchial sample (e.g., bronchoalveolar lavage, bronchial brushing, or lung biopsy) collected during continuous or intermittent treatment of patients with OBR consisting of at least 2 anti-mycobacterial agents according to the current ATS / ERS / ESCMID / IDSA treatment guidelines in at least 6 months of the last 12 months before randomization. If the pre-study respiratory sample is collected >8 weeks to 6 months before randomization, the patient can be enrolled in this study only after the screening sputum sample (hereinafter) is reported as MAC positive by the central microbiology laboratory. In an exemplary embodiment, the human subject has a diagnosis of refractory MAC lung disease composed of the following microbiological criteria:--a screening MAC positive cough or induced sputum sample. The MAC positive culture is based on 2 to 3 screening sputum samples (non-deep bronchial samples) collected during the 8-week screening period, which are sent to the central microbiology laboratory for culture and identification (see laboratory manual for details). If necessary, screening sputum samples can be collected on separate consecutive days; at least 1 sputum sample must have a MAC positive culture for entry. Antimycobacterial susceptibility results are not required prior to randomization. (Note: if a pre-study respiratory specimen was collected within 8 weeks prior to randomization, patients may be enrolled in the study at the investigator's discretion at the time of randomization after collection of a screening sputum specimen with pending (not yet MAC positive) culture results).

[0430] In an exemplary embodiment, the human subjects are able to comply with all study activities and procedures throughout the study, including willingness to comply with a combined antimycobacterial therapy regimen (including inhaled and parenteral medications, as appropriate, and oral medications), and comply with planned study visits and study procedures (including all planned sputum collections) from screening to LFU visit (study duration is up to approximately 20 months, excluding screening). In an exemplary embodiment, the human subjects are expected to survive under continued antimycobacterial therapy and appropriate supportive care from screening to LFU visit, based on the investigator's judgment.

[0431] In an exemplary embodiment, human subjects agree to use effective birth control methods. In an exemplary embodiment, human subjects are women, and are not pregnant or breast-feeding. In an exemplary embodiment, from screening to EOT visits and 90 days after the last dose of ipeborole, human female subjects (FOCP) with fertility potential implement sexual desire abstinence or use at least 2 kinds of medically accepted effective birth control methods, which can be a combination of highly effective methods (such as oral contraceptives, indwelling intrauterine contraceptive devices, hormone implants / patch, injection, or approved neck ring) and barrier methods (such as condoms, spermicidal gel). No fertility potential is defined as postmenopausal (i.e., amenorrhea for at least 1 year) or surgery / natural infertility. In an exemplary embodiment, human subjects are males, and aale patients with FOCP sex active agree to use effective barrier contraceptive methods from screening to EOT visits and 90 days after the last dose of ipeborole.

[0432] In an exemplary embodiment, the human subject does not have predominantly fibrotic cavitary MAC lung disease. In an exemplary embodiment, the human subject does not have a history of treatment-refractory MAC lung disease of ≥5 years. In an exemplary embodiment, the human subject does not have cystic fibrosis or other inherited airway ciliary dysfunction disorders (e.g., primary ciliary dyskinesia). In an exemplary embodiment, the human subject does not have active allergic bronchopulmonary fungal disease. In an exemplary embodiment, the human subject does not have an anticipated or planned lung surgery for the treatment of MAC lung disease. In an exemplary embodiment, the human subject does not have disseminated MAC infection, or other known or suspected non-pulmonary sources of infection (e.g., infective endocarditis, osteomyelitis, meningitis, or urinary tract infection) that require non-investigational antimicrobial therapy. In an exemplary embodiment, the human subject does not have concomitant lung infection requiring antimicrobial therapy, including infection caused by fungi, viruses, non-MAC mycobacteria (e.g., Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium kansasii), or other bacteria (e.g., Pseudomonas aeruginosa, Staphylococcus aureus). In an exemplary embodiment, the human subject does not have active lung malignancies (primary or metastatic) or any malignancies that require or will require chemotherapy or radiation therapy within 1 year prior to randomization by LFU visit. In an exemplary embodiment, the human subject does not have a creatinine clearance (CrCl) of ≤50 mL / min at screening or at randomization, as estimated by the Cockcroft-Gault formula: Estimated CrCl (mL / min) = (140-age [years]) × actual weight [kg] × [0.85 if female]) / (72 × serum creatinine [mg / dL]). In an exemplary embodiment, the human subject does not have a hemoglobin of <10.0 g / dL or <6.2 mmol / L (grade 2 anemia or worse, based on Common Terminology Criteria for Adverse Events [CTCAE] criteria) at screening. In an exemplary embodiment, the human subject has not donated blood or plasma within 28 days prior to treatment. In an exemplary embodiment, the human subject has no symptomatic blood loss or bleeding within 28 days prior to treatment. In an exemplary embodiment, the human subject has no severe hemoptysis within 28 days prior to treatment, defined as >100 mL (approximately >7 tablespoons of blood) or severe or very severe hemoptysis in any 24-hour period.In an exemplary embodiment, the human subject does not have severe liver damage, as evidenced by alanine aminotransferase (ALT) or aspartate aminotransferase (AST)>3x upper limit of normal (ULN) or total bilirubin>2x ULN or clinical signs of cirrhosis or end-stage liver disease (e.g., ascites, hepatic encephalopathy). In an exemplary embodiment, the human subject is not pregnant or breast-feeding. In an exemplary embodiment, the human subject does not have an average QT interval (QTcF) corrected using the Fridericia formula based on triplicate 12-lead ECGs at screening>480 milliseconds. In an exemplary embodiment, the human subject does not have the risk of immunodeficiency or immunocompromised conditions and opportunistic lung infections. Wherein in an exemplary embodiment, the human subject does not have a history of known human immunodeficiency virus (HIV) infection plus active acquired immunodeficiency syndrome (AIDS)-limited diseases in the past 12 months. In an exemplary embodiment, the human subject does not have a known cluster of differentiation 4 (CD4) count <200 / mm in the past 12 months. 3 In an exemplary embodiment, the human subject does not have neutropenia (absolute neutrophil count <1,000 neutrophils / mm 3 ). In an exemplary embodiment, the human subject has not started immunosuppressive therapy, including cancer chemotherapy, transplant rejection drugs, or long-term use of systemic corticosteroids (defined as ≥20 mg / day of prednisone or systemic equivalents) within 8 weeks of randomization. In an exemplary embodiment, it is expected that the human subject will not start a new non-study anti-mycobacterial therapy during the dosage regimen provided herein. In an exemplary embodiment, the human subject has not received any other study drug during the first 30 days or 5 half-lives of treatment (whichever is longer). In an exemplary embodiment, the human subject has not been previously exposed to ipaborol. In an exemplary embodiment, the human subject does not have any condition that interferes with the ability to safely complete this study or comply with the requirements of this study, including the patient's inability or unwillingness to comply with all study assessments and visits.

[0433] In an exemplary embodiment, the methods described herein cannot be administered to a human subject who has undergone a prior treatment as described herein. In an exemplary embodiment, the methods described herein cannot be administered to a human subject who has undergone a contraindicated therapy as described herein. In an exemplary embodiment, the methods described herein can be administered to a human subject who has undergone a concomitant therapy as described herein.

[0434] Miscellaneous

[0435] In an exemplary embodiment, the methods described herein can be administered according to the purposes described in Example 1. In an exemplary embodiment, the dosage regimens described herein can be administered according to the purposes described in Example 1. In an exemplary embodiment, the methods described herein can be administered according to the endpoints described in Example 1. In an exemplary embodiment, administering the dosage regimens described herein can be administered according to the endpoints described in Example 1.

[0436] In an exemplary embodiment, the human subject has been administered at least one previous NTM treatment that is not epaborole. In an exemplary embodiment, the human subject has been administered at least two previous NTM treatments, neither of which is epaborole. In an exemplary embodiment, at least 6 months in the last 12 months before the first dose of the dosage regimen, the previous NTM treatment was selected from at least 2 antimycobacterial agents according to the current international treatment guidelines. In an exemplary embodiment, the previous NTM treatment is selected from clarithromycin, azithromycin, ethambutol, rifampicin, rifabutin, amikacin, bedaquiline, clofazimine, linezolid and fluoroquinolone. In an exemplary embodiment, the method also includes administering an optimized background regimen (OBR) treatment to the human subject. In an exemplary embodiment, the optimized background regimen (OBR) treatment is at least 2 antimycobacterial agents according to the current American Thoracic Society (ATS) / European Respiratory Society (ERS) / European Society of Clinical Microbiology and Infectious Diseases (ESCMID) / American Infectious Diseases Society (IDSA) treatment guidelines.

[0437] All cited references are expressly incorporated herein by reference in their entirety.

[0438] While specific embodiments of the present invention have been described above for purposes of illustration, it will be appreciated by those skilled in the art that numerous changes in detail may be made without departing from the invention as described in the appended claims.

[0439] All publications, patents, patent applications, and other documents cited in this application are incorporated herein by reference in their entirety for all purposes, to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated herein by reference for all purposes. In the event of an inconsistency between the teachings of one or more references incorporated herein and the present disclosure, the teachings of the present specification shall control. Example

[0440] The following examples are provided to illustrate the present invention. These examples are not meant to limit the present invention to any particular application or theory of operation.

[0441] General and specific scientific techniques are summarized in U.S. Patent 7,816,344, and PCT Publication No. WO 2008 / 157726 Al, which are each expressly incorporated herein by reference in their entireties, particularly for the techniques summarized therein.

[0442] Example 1

[0443] Treatment plan

[0444] Phase 2 Goals and Endpoints

[0445] The primary objective of Phase 2 is to evaluate the microbiologic response to oral ipeborole compared with placebo. Another primary objective of Phase 2 is to evaluate the safety of oral ipeborole compared with placebo. A secondary objective of Phase 2 is to evaluate the plasma PK of oral ipeborole; the dose of ipeborole can be confirmed based on PK analysis from approximately 16 patients on ipeborole.

[0446] An exploratory objective of phase 2 was to assess clinical and microbiologic responses in subgroups (e.g., age, use of amikacin liposomal inhalation suspension [ALIS] at baseline [pre-randomization], MAC resistance phenotype). Another exploratory objective of phase 2 was to assess lung radiographic response. Another exploratory objective of phase 2 was to assess microbiologic response with ipelborole MIC. Another exploratory objective of phase 2 was to assess the reduced susceptibility of post-baseline MAC isolates to ipelborole compared with baseline. Another exploratory objective of phase 2 was to assess the duration of microbiologic response. Another exploratory objective of phase 2 was to assess microbiologic reinfection and relapse.

[0447] The primary endpoint of Phase 2 is by-subject sputum conversion monthly through Month 6. Sputum conversion can be assessed using MAC-negative sputum cultures based on 3 consecutive months. Another primary endpoint of Phase 2 is to assess changes from baseline in TEAEs and clinical laboratory values, electrocardiograms (ECGs), and vital signs.

[0448] The secondary endpoint for Phase 2 is microbiological improvement per subject monthly through Month 6. Microbiological improvement can be assessed using a reduction in MAC colony counts of Class ≥ 1 as described herein. Another secondary endpoint is characterization of PK parameters (e.g., Vd, Cmax, AUC) in the epaborole recipient.

[0449] The exploratory endpoints of Phase 2 were clinical response and microbiological response (sputum culture conversion by subject and microbiological improvement by subject) at Months 3 and 6, represented by age category, ALIS use at baseline, and MAC resistance phenotype (i.e., macrolide resistance and amikacin resistance). Another exploratory endpoint of Phase 2 was radiological response at Month 6 and end of treatment (EOT), defined as the overall change from baseline based on blinded central readings of chest computed tomography (CT). The exploratory endpoint of Phase 2 was subject microbiological response (sputum culture conversion by subject and microbiological improvement by subject) by ipembro MIC at Month 6. Another exploratory endpoint of Phase 2 was the rate of susceptibility reduction in post-baseline MAC isolates, defined as an increase of ≥4-fold in ipembro MIC relative to the baseline isolate MIC in patients who remained MAC culture positive at Month 4 or later. Another exploratory endpoint of Phase 2 was the time to first negative sputum culture (in months) and a reduction of ≥1 category in MAC colony count. An additional exploratory endpoint in phase 2 was the rates of reinfection (new pulmonary MAC infection caused by a pathogen different from the baseline MAC isolate, as determined by molecular typing) and relapse (pulmonary MAC infection caused by the same baseline MAC isolate, as determined by molecular typing) at month 6.

[0450] Phase 3 Goals and Endpoints

[0451] The primary objective of Phase 3 is to determine whether ipeborole + OBR is superior to placebo + OBR in terms of microbiological response. A secondary objective of Phase 3 is to evaluate the safety of oral ipeborole compared with placebo. Another secondary objective of Phase 3 is to evaluate the plasma PK of oral ipeborole. An exploratory objective of Phase 3 is to evaluate clinical and microbiological responses in subgroups (e.g., age, ALIS use at baseline, MAC resistance phenotype). Another exploratory objective of Phase 3 is to evaluate lung radiographic response. Another exploratory objective of Phase 3 is to evaluate microbiological response by ipeborole MIC. Another exploratory objective of Phase 3 is to evaluate the reduced susceptibility of post-baseline MAC isolates to ipeborole compared with baseline. Another exploratory objective of Phase 3 is to evaluate the duration of microbiological response. Another exploratory objective of Phase 3 is to evaluate microbiological reinfection and recurrence.

[0452] The primary endpoint of Phase 3 is the sputum conversion of subjects based on 3 consecutive months of negative sputum culture of MAC to the 6th month. The secondary endpoint of Phase 3 is the microbiological improvement of subjects at the 3rd and 6th months using ≥1 category MAC colony count reduction. Another secondary endpoint of Phase 3 is to evaluate the changes in TEAEs and clinical laboratory values, ECG and vital signs from baseline. Another secondary endpoint of Phase 3 is the characterization of PK parameters (such as Vd, Cmax, AUC) in eperborole recipients. The exploratory endpoints of Phase 3 are clinical response and microbiological response (conversion of sputum culture by subjects and microbiological improvement by subjects) at the 3rd and 6th months, which are presented by age category, ALIS use at baseline and MAC resistance phenotype (macrolide resistance and amikacin resistance). Another exploratory endpoint of Phase 3 is the radiographic response and EOT at the 6th month, defined as the overall change from baseline in the blinded central reading based on chest CT. Another exploratory endpoint in Phase 3 was the microbiological response per subject (sputum culture conversion per subject and microbiological improvement per subject) by ipelborole MIC at Month 6. Another exploratory endpoint in Phase 3 was the rate of susceptibility reduction in post-baseline MAC isolates, defined as a ≥4-fold increase in ipelborole MIC relative to the baseline isolate MIC in patients who remained MAC culture positive at Month 4 or later. Another exploratory endpoint in Phase 3 was the time to first negative sputum culture (in months) and a ≥1 category reduction in MAC colony count. Another exploratory endpoint in Phase 3 was the reinfection rate (new pulmonary MAC infection caused by a strain different from the baseline MAC isolate, as determined by molecular typing) and relapse rate (pulmonary MAC infection caused by the same baseline MAC isolate, as determined by molecular typing) at Month 6, EOT, and late visit (LFU).

[0453] Study Design

[0454] This is a Phase 2 / 3, double-blind, placebo-controlled study of ipeborole + OBR (optimal background regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. The study can enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria. In addition to meeting the clinical criteria required for the disease definition, microbiological criteria also define "treatment-refractory" MAC lung disease as a respiratory sample culture positive for MAC when the patient was treated continuously or intermittently with an OBR consisting of at least 2 antimycobacterial agents according to current international treatment guidelines for at least 6 of the last 12 months before randomization. Randomization can be stratified according to baseline use of amikacin liposomal inhalation suspension (ALI) and age at informed consent (<65 years vs. ≥65 years).

[0455] This study was characterized by a sequential Phase 2 / 3 approach, with initial Phase 2 assessments of symptom-based clinical response, microbiologic response, safety, and PK associated with oral epaborole prior to analyses of superiority of oral epaborole versus placebo in the Phase 3 portion of the study.

[0456] In the Phase 2 portion of the study, approximately 80 patients will be randomized in a 1:1 ratio (40 patients to receive active ipeborole tablets and 40 patients to receive matching placebo tablets) using an interactive response technology (IRT) system.

[0457] The sponsor may unblind the Phase 2 data analysis after the last patient in Phase 2 completes the Month 6 visit. Patients, investigators, and other research staff may also remain blinded to treatment assignment during the last study visit (LFU). Phase 2 data analysis may include review of microbiology, safety, and PK data collected at multiple time points over 6 months. The Phase 3 portion of the study may begin recruiting after the last patient in the Phase 3 dose is confirmed after reviewing the PK data from Phase 2. Patients who participated in the Phase 2 portion of the study are not eligible to participate in Phase 3. Patients in Phase 2 may continue to take blinded study medication for 12 months after the first negative MAC culture that defines sputum culture conversion; in patients who remain MAC culture-positive despite 6 months of treatment with study medication, study medication may be discontinued (based on Month 4 sputum culture results).

[0458] The figure below represents the design of this study.

[0459]

[0460] * Patients with culture conversion will be treated according to treatment guidelines for 12 months starting from the first negative culture.

[0461] EOT = end point of treatment; LFU = late follow-up; OBR = optimized background regimen; TBD = final sample size to be confirmed based on data from the Phase 2 portion.

[0462] The Phase 3 portion of the study may test the superiority of ipeborole plus OBR compared with placebo plus OBR. In this portion of the study, approximately 234 patients are planned to be randomized in a 2:1 ratio using the IRT system (156 patients to receive active ipeborole tablets and 78 patients to receive matching placebo tablets). In addition, the sponsor may determine whether the Phase 3 sample size should be adjusted and will validate the Phase 3 ipeborole dosing regimen based on observed plasma ipeborole exposure. The sponsor may unblind the Phase 3 data analysis after the last patient in Phase 3 completes the Month 6 visit; patients, investigators, and other study personnel may remain blinded to treatment assignment during the last study visit (LFU). The Phase 3 data analysis will include a review of patient-reported clinical symptom response, microbiology, safety, and PK data collected at multiple time points over 6 months. Patients in Phase 3 could continue double-blind study drug for 12 months after the first negative MAC culture defining sputum culture conversion; in patients who remained MAC culture positive despite 6 months of treatment with study drug, study drug could be discontinued (based on the 4th month sputum culture results).

[0463] During the conduct of this study, an independent Data and Safety Monitoring Board (DSMB) may be responsible for periodically reviewing unblinded study safety data by performing qualitative and quantitative safety assessments. In addition, the DSMB may determine whether the underlying study hypotheses remain valid and assess whether the overall integrity, scientific merit, and conduct of the study remain acceptable. The DSMB may recommend to the sponsor to continue or terminate the study or recommend changes to the study design / procedures.

[0464] Study Assessment and Methodology

[0465] For the Phase 2 and Phase 3 portions of this study, study assessments and procedures can be completed at the following visits:

[0466] Screening visit : Screening assessments to determine study eligibility may be performed up to 8 weeks prior to randomization. Two to three sputum samples may be collected during the screening period and may be collected on separate consecutive days. Screening sputum samples may be sent to a central microbiology laboratory (National Jewish Lab) for culture, identification, quantitation, sensitivity testing, and molecular testing. If a pre-study MAC-positive respiratory specimen was collected within 8 weeks prior to randomization, patients may be enrolled in the study after collection of the screening sputum sample and pending (not yet MAC-positive) screening culture results.

[0467] Antimycobacterial susceptibility results were not required prior to randomization. If a pre-study MAC-positive respiratory specimen was collected >8 weeks to 6 months prior to randomization, patients could be enrolled in the study after a screening sputum specimen was reported as MAC-positive by the central microbiology laboratory (only identification of the MAC level, not the species level, was required for randomization).

[0468] Notice Patients whose post-randomization screening sputum sample cultures were ultimately negative for MAC may prematurely discontinue study drug if the final screening pending culture is reported as negative, and their OBR may continue; however, they may remain in the study (i.e., they will not be withdrawn from the study) to undergo all planned EOT and LFU assessments, including safety assessments.

[0469] Treatment period : Patients can receive blinded study drug (eiperborole or placebo) from Day 1 to EOT. For patients who are culture converters by Month 6, or when study drug is discontinued prematurely for any reason, EOT can be up to 12 months from the time of first sputum culture conversion to negative MAC culture. Patients who remain MAC culture positive despite 6 months of treatment with study drug (based on Month 4 sputum culture results) can discontinue study drug. Reporting of final respiratory culture and identification results can be performed up to 8 weeks after receipt of the specimen by the central laboratory.

[0470] During the first 6 months of the treatment period, study assessments (including microbiologic, clinical, safety, and PK assessments) may be performed starting from Day 1 (calendar day of the first dose of study drug) and every 28 days (± 7 days) thereafter until Month 6 (Day 169 ± 7 days).

[0471] Patients with culture conversion based on 3 consecutive MAC-negative sputum cultures prior to Month 6 (Day 169±7) may continue blinded study drug for 12 months (Investigators, study sites, and patients will remain blinded) from the first month of defined sputum culture conversion, up to a total of 16 months.

[0472] For patients who continued blinded study drug during the treatment period after Month 6, study assessments (including microbiological, clinical, safety, and PK assessments) could be performed every 3 months (84 days ± 7 days) thereafter until EOT (up to 12 months from the time of first sputum culture conversion to negative MAC culture).

[0473] EOT visit: The EOT visit is performed within 7 calendar days after the last dose of study drug. Patients who require more than a maximum of 16 months of MAC lung disease treatment for any reason can stop the study drug and be treated with an appropriate open-label anti-mycobacterial regimen. EOT can occur up to 12 months after the first negative respiratory culture of MAC (i.e., the first month of sputum MAC culture conversion), or when the study drug is prematurely discontinued for any reason, including persistent positive culture despite 6 months of study drug treatment. For patients who withdraw from the study before completion, the EOT visit can be performed at the Early Termination Visit. If within the EOT window, the EOT assessment can be performed during a regularly scheduled clinic visit.

[0474] LFU Visit : The LFU visit can be performed 3 months (84 days ± 14 days) after the last dose of study drug.

[0475] Patients who prematurely discontinued study drug for any reason could remain in the study (ie, not withdraw from the study) for all planned EOT and LFU assessments, including safety assessments.

[0476] Participation Period

[0477] For the Phase 2 and Phase 3 portions of the study, the duration of study participation for each patient (excluding screening) may be up to about 19 months.

[0478] The duration of each patient's participation in the study varies according to the time of microbial sputum MAC culture conversion. In order to receive study drug after the 6th month, subjects can achieve microbial sputum MAC culture conversion based on 3 consecutive months of negative sputum culture at the 6th month. Patients can continue to take blinded study drug for 12 months after the first month of defining sputum culture conversion, up to 16 months. In patients who remain MAC culture positive despite 6 months of treatment with study drug, study drug can be discontinued (based on sputum culture results at the 4th month).

[0479] For example, a subject with 3 consecutive negative results at Months 4, 5, and 6 can continue blinded study drug for an additional 12 months from Month 4 (the first month of conversion) to Month 16. The EOT visit for this subject will be at Month 16 (i.e., 12 months after Month 4), and the LFU visit will be at Month 19 (i.e., 3 months [84 days ± 14 days] after the last dose).

[0480] Inclusion Criteria

[0481] Inclusion criteria for study subjects include: 1. Male or female patients 18 years of age or older. 2. Willing and able to provide written informed consent. 3. Patients with a diagnosis of treatment-refractory MAC lung disease consisting of the following microbiological and / or radiographic criteria: Microbiological criteria: - One pre-study MAC-positive respiratory specimen. In an exemplary embodiment, the specimen is collected within 6 months prior to screening based on documentation in the patient's medical record. In an exemplary embodiment, documentation of the collection of MAC-positive specimens according to the standard of care within 6 months prior to signing the informed consent form (ICF) is provided. In an exemplary embodiment, the respiratory specimen is a cough or induced sputum specimen or deep bronchial specimen (e.g., bronchoalveolar lavage, bronchial brushing, or lung biopsy) collected while the patient is being treated continuously or intermittently with an OBR consisting of at least 2 antimycobacterial agents according to current American Thoracic Society (ATS) / European Respiratory Society (ERS) / European Society for Clinical Microbiology and Infectious Diseases (ESCMID) / Infectious Diseases Society of America (IDSA) treatment guidelines, for at least 6 months of the last 12 months prior to randomization. In an exemplary embodiment, the pre-study is collected during continuous or intermittent treatment with OBR consisting of at least 2 anti-mycobacterial agents according to the current American Thoracic Society (ATS) / European Respiratory Society (ERS) / European Society of Clinical Microbiology and Infectious Diseases (ESCMID) / American Infectious Diseases Society (IDSA) treatment guidelines, for at least 6 months of the 12 months before randomization. In an exemplary embodiment, if the pre-study respiratory sample is collected >8 weeks to 6 months before randomization, the patient can only participate in the study after the screening sputum sample is reported as MAC positive by the central microbiology laboratory. In an exemplary embodiment, the pre-study respiratory sample can be a coughed or induced sputum sample, or a deep bronchial sample (e.g., bronchoalveolar lavage, bronchial brushing or lung biopsy). --A screening MAC positive coughed or induced sputum sample. In an exemplary embodiment, MAC positive culture is based on 2 to 3 screening sputum samples (not deep bronchial samples) collected during the 8-week screening period, which are sent to the central microbiology laboratory for culture and identification. In an exemplary embodiment, MAC-positive culture is based on 2 to 3 screening sputum samples (not deep bronchial samples) collected during the 8-week screening period (after signing the ICF) and sent to the central microbiology laboratory for culture and identification. In an exemplary embodiment, screening sputum samples can be collected on separate consecutive days if necessary; at least 1 sputum sample must have a MAC-positive culture for inclusion. In an exemplary embodiment, screening sputum samples can be collected on the same day or on separate consecutive days. Antimycobacterial sensitivity results are not required before randomization.If a prestudy MAC-positive respiratory specimen was collected >8 weeks to 6 months before randomization, patients could be enrolled in the study only after the screening sputum specimen was reported as MAC positive by the central microbiology laboratory. If a prestudy MAC-positive respiratory specimen was collected within 8 weeks before randomization, patients could be enrolled after the screening sputum specimen was collected and pending (not yet MAC-positive) screening culture results (at the discretion of the investigator). Radiographic Criteria: Chest CT scan performed within 8 weeks before randomization with abnormalities consistent with MAC lung disease. NOTE: MAC lung disease with radiographic evidence of a cavity was allowed if the maximum diameter of the largest cavity on chest CT was ≤3.0 cm. Patients with predominantly fibrocavitary MAC lung disease or the presence of any cavity with a diameter >3.0 cm were excluded. 4. Patients are willing to comply with all study activities and procedures throughout the study, including willingness to adhere to the combined antimycobacterial treatment regimen (including inhaled and parenteral medications, as appropriate, and oral medications) and comply with all planned study visits and study procedures (including all planned sputum collections) from screening to the LFU visit (study duration is up to approximately 19 months, excluding screening). 5. All patients must agree to use an effective method of birth control. a. Female patients must not be pregnant or nursing. Female patients of childbearing potential (FOCP) must be abstaining from sex or using at least 2 medically accepted effective methods of birth control, which may include a combination of highly effective methods (e.g., oral contraceptives, indwelling intrauterine devices, hormonal implants / patch, injections, or approved cervical rings) and barrier methods (e.g., condoms, spermicidal gel) from screening to the EOT visit and 90 days after the last dose of study medication. No childbearing potential is defined as postmenopausal (i.e., amenorrhea for at least 1 year) or surgical / natural infertility. b. Sexually active male patients with FOCP must agree to use an effective barrier method of contraception from Screening to the EOT visit and for 90 days after the last dose of study medication. 6. Patients are expected to survive with continued antimycobacterial therapy and appropriate supportive care from Screening to the LFU visit.

[0482] Elimination criteria

[0483] Elimination criteria for subjects in this study include: 1. Patients with any suspected or confirmed disease or condition at screening or randomization that, in the opinion of the investigator, may confound the assessment of symptom-based clinical response, including but not limited to the following: predominantly cavitary MAC lung disease or any cavity with a diameter >3.0 cm on radiography; history of treatment-refractory MAC lung disease >5 years; cystic fibrosis or other inherited airway ciliary dysfunction diseases (e.g., primary ciliary dyskinesia); active allergic bronchopulmonary fungal disease; anticipated or planned lung surgery for the treatment of MAC lung disease; disseminated MAC infection, or other known or suspected non-pulmonary sources of infection requiring non-study antimicrobial therapy (e.g., infective endocarditis, osteomyelitis, meningitis, or urinary tract infection); Concomitant pulmonary infection requiring antimicrobial therapy, including infections caused by fungi, viruses, non-MAC mycobacteria (e.g., Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium kansasii), or other bacteria (e.g., Pseudomonas aeruginosa, Staphylococcus aureus); Note: Patients with MAC lung disease and concomitant non-MAC lung infection requiring antimicrobial therapy may complete antimicrobial therapy prior to randomization. Patients whose respiratory specimen cultures contain growth of non-MAC organisms, who are considered by the investigator to be respiratory colonizers, and who do not require or receive specific antimicrobial therapy may remain eligible. 2. Patients with active pulmonary malignancy (primary or metastatic) or any malignancy that requires or will require chemotherapy or radiation therapy at the LFU visit within 1 year prior to randomization. 3. Patients with creatinine clearance (CrCl) ≤ 50 mL / min at screening or at randomization, as estimated by the Cockcroft-Gault formula: estimated CrCl (mL / min) = (140-age [years]) × actual weight [kg] × [0.85 if female]) / (72 × serum creatinine [mg / dL]). 4. Patients with hemoglobin <10.0 g / dL or <6.2 mmol / L (grade 2 anemia or worse, based on Common Terminology Criteria for Adverse Events [CTCAE] criteria) at screening; donated blood or plasma within 28 days prior to randomization; or symptomatic blood loss or bleeding within 28 days prior to randomization. 5. Patients with severe hemoptysis within 28 days prior to randomization, defined as >100 mL (approximately >7 tablespoons of blood) in any 24-hour period. 6. Patients with severe liver impairment, as evidenced by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x upper limit of normal (ULN) or total bilirubin >2x ULN, or clinical signs of cirrhosis or end-stage liver disease (e.g., ascites, hepatic encephalopathy). 7. Patients who are pregnant or breastfeeding. 8. Patients with a mean QT interval (QTcF) >480 milliseconds based on triplicate 12-lead ECGs corrected using the Fridericia formula at screening.9. Patients with immunodeficiency or immunocompromising conditions who are at risk for opportunistic lung infections, including: a known history of human immunodeficiency virus (HIV) infection plus active acquired immunodeficiency syndrome (AIDS)-defining illness in the past 12 months, or a known cluster of differentiation 4 (CD4) count <200 / mm in the past 12 months. 3 ; Neutropenia at screening (absolute neutrophil count <1,000 neutrophils / mm 3 ); or initiated immunosuppressive therapy within 8 weeks prior to randomization, including cancer chemotherapy, transplant rejection drugs, or long-term use of systemic corticosteroids (defined as 320 mg / day of prednisone or systemic equivalent). 10. Patients who are expected to start new non-study antimycobacterial therapy, which will be given at any time between screening and Month 6 (Day 169±7). 11. Patients who have received any study drug during the 30 days or 5 half-lives (whichever is longer) prior to randomization. 12. Patients with any prior exposure to ipeborole. 13. Patients with any condition that the investigator believes interferes with the ability to safely complete the study or comply with study requirements, including patients unable or unwilling to comply with all study assessments and visits.

[0484] Withdrawal from the study

[0485] The patient's participation in this clinical study may be interrupted for any of the following reasons, including but not limited to: - the patient withdraws consent or requests to interrupt the study for any reason; - the patient is lost to follow-up; - the patient fails to comply with the protocol requirements or study-related procedures; - the investigator determines that it is in the best interest of the patient to withdraw from the study protocol for reasons other than AEs (such as the occurrence of any medical condition or situation that exposes the patient to significant risks and / or does not allow the patient to comply with the protocol requirements); - the study is terminated or temporarily suspended by the sponsor or regulatory agency for any reason, including but not limited to unexpected life-threatening serious AEs (SAEs) related to the study drug detected during safety monitoring.

[0486] Premature discontinuation of study drug

[0487] Premature discontinuation of study drug by the investigator is an important discussion that should include a medical monitor, if feasible, prior to study drug discontinuation.

[0488] Possible reasons for premature discontinuation of study drug for safety reasons include, but are not limited to, the following: - Occurrence of an AE for which the investigator believes the patient should permanently discontinue study drug administration; - Meeting Hy's Law criteria, defined as an increase in ALT of at least 3 times or AST>ULN, an increase in serum total bilirubin to >2x ULN without an increase in serum alkaline phosphatase, and no other disease or condition found to explain the liver test abnormalities; - Known pregnancy or breastfeeding during study drug administration; - Decreased renal function after baseline with estimated CrCl less than or equal to 50 mL / min; - Positive sputum cultures persist beyond the 6th month of treatment; - Screening sputum sample cultures after randomization ultimately determined to be MAC without growth (culture negative). NOTE: Reporting of final respiratory culture and identification results may occur up to 8 weeks after receipt of the sample by the central laboratory. Patients who prematurely discontinue study drug will remain on study for safety visits (i.e., will not be withdrawn from the overall study) unless the patient withdraws consent and will be evaluated at the EOT and LFU visits.

[0489] Unit Dosage Form & Route of Administration

[0490] The following unit dosage forms and routes of administration were used: Iperborole oral tablet: 250 mg; Iperborole dose: 500 mg (two 250 mg oral tablets), once daily (QD); Placebo oral tablet: matched to Iperborole tablet; Placebo regimen: matched to Iperborole dose (2 oral tablets QD).

[0491] Eligible patients were randomized to 1 of the following treatment groups: a) ipeborole oral tablet 500 mg (two 250 mg oral tablets) QD + OBR; or b) placebo oral tablet matched to ipeborole dose QD + OBR. In this study, OBR at the time of randomization must consist of at least 2 oral antimycobacterial drugs administered in accordance with current ATS / ERS / ESCMID / IDSA treatment guidelines.

[0492] A total of approximately 314 patients will be enrolled in this Phase 2 / 3 study: The Phase 2 portion of the study may consist of approximately 80 randomized patients (40 patients in the iperborole + OBR group and 40 patients in the placebo + OBR group). The Phase 3 portion of the study may consist of approximately 234 randomized patients (156 patients in the iperborole + OBR group and 78 patients in the placebo + OBR group). The number of patients in the Phase 3 portion of the study may be adjusted based on the results of the Phase 2 analysis.

[0493] Labelling, packaging, storage and handling

[0494] Iperborole is provided as a white to off-white modified oval, film-coated IR tablet for oral administration containing 250 mg of Iperborole free base (288.5 mg as the hydrochloride salt). A color-matched placebo tablet may also be provided.

[0495] Study Drug Administration

[0496] Active ipeborole and matching placebo oral tablets may be administered at a dose of 500 mg QD. Study drug tablets may be administered in the fasting state (no food for at least 1 hour before and at least 2 hours after study drug administration). If GI discomfort occurs on an empty stomach with study drug, study drug administration may be taken with a small snack or administered at bedtime to improve tolerability.

[0497] The first dose of study drug may be administered in the presence of the Investigator or designee after randomization on Day 1. Following the first dose of study drug, patients will orally self-administer QD study drug. Interactive Response Technologies and Investigational Drugs Distribution of Things

[0498] The IRT system is used for study drug management tasks. This can include randomization, study drug supply management, inventory management and supply ordering, study drug expiration tracking, and emergency unblinding.

[0499] Once informed consent is obtained, patients will be assigned a unique 9-digit patient identifier at the time of screening.

[0500] The first approximately 80 patients in this study will be randomized in a 1:1 ratio to Phase 2 using the IRT system (40 patients to receive active ipelborole tablets and 40 patients to receive matching placebo tablets). For the Phase 3 portion of the study, approximately 234 patients are planned to be randomized in a 2:1 ratio using the IRT system (156 patients to receive active ipelborole tablets and 78 patients to receive matching placebo tablets).

[0501] Timing of study drug dose administration

[0502] The first dose of study drug may be administered in the presence of the Investigator or designee as soon as possible after randomization on Day 1. After the first dose of study drug, adjustment of the time of daily study drug administration is permitted to coincide with the patient-specific medication administration schedule in the management of therapeutic MAC lung disease.

[0503] Dosing was studied in patients with normal renal function or mild renal impairment

[0504] Patients with CrCl ≤ 50 mL / min were excluded from the study. Following enrollment into the study, patients will undergo regular safety assessments, including routine monitoring of renal function (eg, serum creatinine) during the study.

[0505] Renal function as estimated by CrCl will be assessed using the Cockcroft-Gault formula and serum creatinine levels obtained at the central laboratory before Day 1 and as needed throughout the study at each routine standard of care visit; in addition, serum creatinine levels measured by the central laboratory will determine CrCl as per protocol.

[0506] Cockcroft-Gault formula: Estimated CrCl (mL / min) = (140-age [years]) × actual weight [kg] × [0.85 if female]) / (72 × serum creatinine [mg / dL])

[0507] Estimated CrCl can be calculated each time a local laboratory assessment of serum creatinine is performed. Actual weight in kilograms (not ideal weight) is required for CrCl calculation. If available, body weight obtained on the day of serum creatinine measurement can be used to calculate CrCl; however, if repeated weights are not available, baseline weight or most recent weight can be used for estimated CrCl calculations throughout the study.

[0508] After Day 1, if the estimated CrCl decreases to ≤50 mL / min during treatment, serial serum creatinine levels and CrCl estimates should be performed to determine whether the study drug should be withheld or prematurely discontinued. The investigator may choose to continue monitoring the patient and reassess the need for premature discontinuation of the study drug based on subsequent CrCl assessments. If repeated CrCl estimates are ≤50 mL / min, the study drug may be discontinued.

[0509] Study dosing in patients with anemia

[0510] Patients with a baseline hemoglobin <10.0 g / dL or <6.2 mmol / L (grade 2 anemia or worse, based on CTCAE criteria) may be excluded from this study. Reductions in RBC parameters, including hemoglobin, RBC, and reticulocyte counts, have been reported in subjects receiving IV or oral ipeborole. In previous Phase 1 and Phase 2 studies of IV or oral ipeborole, a decrease in reticulocytes followed by a decrease in hemoglobin was observed within the first few days of administration. These hematologic abnormalities were apparently transient, occurred gradually, and returned to baseline values ​​after discontinuation of ipeborole when followed over time.

[0511] Anemia was predefined as an adverse event of special interest. If anemia occurred during the study, the hematology values ​​should be rechecked in the local laboratory to verify the results and workup should be performed to determine the cause of the anemia based on his / her best clinical judgment (including but not limited to iron deficiency [e.g., check serum iron panel], GI bleeding, menstruation, concomitant medications [e.g., nonsteroidal anti-inflammatory drugs, rifamycins, oxazolidinones, clofazimine], vitamin deficiencies [e.g., vitamin B 12 , folic acid] and hemolysis [e.g., assessment of haptoglobin, blood smear]). Because epaborole has the potential to affect only erythropoiesis and not the production of other blood cell types (e.g., lymphocytes, basophils, eosinophils, neutrophils, monocytes, or platelets), anemia associated with leukopenia or thrombocytopenia should prompt investigation of other potential causes.

[0512] If Grade 3 anemia or worse (hemoglobin <8.0 g / dL or <4.9 mmol / L) is identified at any time after the start of blinded study drug treatment, the investigator should recheck the hematology values ​​at the local laboratory to verify the results and perform post-processing to determine the cause of the above anemia. If the investigator believes that post-baseline Grade 3 anemia or worse is related to the blinded study drug, the study drug should be temporarily discontinued. The interruption should not exceed 6 weeks. In this case, the hemoglobin level should be monitored approximately every 1 to 2 weeks to ensure improvement of at least 1 grade.

[0513] All clinically significant abnormal hematologic values ​​should be followed until they return to normal, stabilize, or are no longer clinically significant on repeat testing. Cases should be discussed with the Medical Monitor prior to restarting study drug after improvement or resolution of anemia. Cases should be discussed with the Medical Monitor prior to any interruption or premature discontinuation of study drug.

[0514] Dosing interruptions, incomplete doses, and missed doses

[0515] Protocol deviations were recorded for noncompliance with the pre-specified dosing regimen (oral study drug administered QD), including missed doses or doses administered outside the window period.

[0516] If administration is interrupted or incomplete, no adjustment of the administration regimen is required.

[0517] If a dose is missed for any reason, the next scheduled dose should be administered as soon as possible upon discovery and the remaining doses should be administered at pre-scheduled daily intervals starting the next day (ie, the previous dosing regimen should remain unchanged).

[0518] Investigators are encouraged to discuss the option of continuing study drug administration on a case-by-case basis with the medical monitor following interruptions in dosing, incomplete, or missed doses.

[0519] Prior and concomitant medications and contraindications to treatment

[0520] Prior therapy

[0521] For the purpose of evaluating inclusion criteria, all prior treatments include all treatments received within 6 weeks prior to the date and time of first administration of study drug (including over-the-counter treatments such as herbal supplements, vitamins, dietary aids, and hormone supplements). Patient records of prior treatments may be documented in the appropriate eCRF.

[0522] Concomitant therapy

[0523] Concomitant medications or treatments (including endpoints) administered between the date and time of the first dose of study drug and the last study visit were listed in the appropriate eCRF. Concomitant administration of new, additional non-study specific antimycobacterial therapy that is potentially effective against MAC for reasons other than microbiological failure of study drug (in therapeutic index MAC lung infection) was not permitted; however, changes in the dose of existing antimycobacterial agents were permitted as needed. Any questions regarding the use of concomitant non-study specific systemic antibiotic therapy may be presented to the Medical Monitor prior to administration.

[0524] Contraindications

[0525] The following medications and treatments were prohibited: - any anticipated or planned lung surgery for MAC lung disease; - use of immunosuppressive therapy within 8 weeks prior to randomization and throughout the treatment period, including cancer chemotherapy, transplant rejection drugs, or long-term use of systemic corticosteroids (defined as greater than or equal to 20 mg / day of prednisone or systemic equivalent); - new, additional non-study specific antimycobacterial therapy that is potentially effective against MAC, at any time between screening and Month 6 (Day 169 ± 7; blinded study drug [based on Month 4 sputum culture results]) will be discontinued in patients who remain culture-positive for MAC despite 6 months of treatment with study drug, for reasons other than microbiological failure of study drug (in therapeutic index MAC lung infection), note: any change in the dose of existing antimycobacterial agents was allowed as needed; - any treatment with study drug for 30 days or 5 half-lives (whichever is longer) prior to randomization and throughout the treatment period.

[0526] Patients receiving contraindicated therapy may be excluded from the per-protocol population. Eperiborol should be used with caution in patients with pre-existing anemia, patients receiving concomitant medications that cause anemia, or patients with comorbid conditions that are unrelated to the condition under study and may be significantly impaired by a potential decrease in hemoglobin. Any questions regarding the use of concomitant non-study specific therapy should be directed to the Medical Monitor prior to administration.

[0527] Permitted concomitant therapy

[0528] Concomitant medications are permitted except for those contraindicated as described herein.

[0529] Investigator Guidelines: Use of ALIS (Amikacin Liposomal Inhalation Suspension) Before and During This Study

[0530] For ALIS use at baseline, the following should be considered:- If ALIS has not been administered prior to study enrollment : Since ALIS is recommended for the treatment of refractory MAC lung disease according to current treatment guidelines, investigators and potential patients must consider its use instead of study enrollment. If a decision is made to enroll patients into this study without prior administration of ALIS therapy, the rationale for not administering ALIS must be clearly stated in the source documentation (e.g., patient decision, investigator decision, contraindications to use, unavailability, high a priori likelihood of ALIS-related AEs). In an exemplary embodiment, neither ALIS nor any other new MAC-specific therapy other than blinded study drug may be started during the treatment phase of the study; -- If ALIS was administered prior to the study and will continue during the study : If micro...

Claims

1. A method of achieving a positive treatment response against a nontuberculous mycobacterium (NTM) infection, comprising: Administering to a human subject in need of treatment Eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof; and Ethambutol or a hydrate, a solvate or a pharmaceutically acceptable salt thereof, A positive therapeutic response is thereby achieved.

2. The method of claim 1, wherein eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered in an oral dose of about 250 mg to about 1000 mg.

3. The method of claim 1, wherein eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 450 mg to 550 mg.

4. The method of claim 1, wherein eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 500 mg.

5. The method of claim 1, wherein the eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is eperborole hydrochloride.

6. The method of claim 1, wherein ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 10 mg / kg to about 30 mg / kg.

7. The method of claim 1, wherein ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 13 mg / kg to about 17 mg / kg.

8. The method of claim 1, wherein ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 15 mg / kg.

9. The method of claim 1, wherein ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 23 mg / kg to about 27 mg / kg.

10. The method of claim 1, wherein ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered at an oral dose of about 25 mg / kg.

11. The method of claim 1, wherein said administering continues until said positive therapeutic response is achieved.

12. The method of claim 1, wherein said administering continues in the presence of said positive therapeutic response.

13. The method of the above claim, wherein the administration is performed according to a dosage regimen comprising: administering an oral dose of about 250 mg to about 1000 mg of epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof daily or every other day; and An oral dosage of about 10 mg / kg to about 30 mg / kg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered daily or three days per week.

14. The method of the above claim, wherein the administration is performed according to a dosage regimen comprising: administering an oral dose of about 450 mg to about 550 mg of epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof per day; and An oral dosage of about 13 mg / kg to about 17 mg / kg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered daily.

15. The method of the above claim, wherein the administration is performed according to a dosage regimen comprising: administering an oral dose of about 450 mg to about 550 mg of epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof per day; and An oral dose of about 23 mg / kg to about 27 mg / kg of ethambutol or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered three days per week.

16. The method of claim 13 or 14 or 15, wherein the dosage regimen lasts from about 27 to about 29 days.

17. The method of claim 16, wherein said dosage regimen is repeated until said positive therapeutic response is achieved.

18. The method of claim 16, wherein said dosage regimen is repeated in the presence of said positive therapeutic response.

19. The method of claim 16, wherein said dosage regimen is administered to said human subject as long as said positive therapeutic response occurs.

20. The method of claim 16, wherein the dosage regimen is repeated two or three or four or five times.

21. The method of claim 16, wherein the dosage regimen is repeated about fifteen to thirty times.

22. The method of claim 16, wherein the dosage regimen is repeated fifteen times or sixteen times or seventeen times or eighteen times or nineteen times or twenty times.

23. The method of any one of claims 2-22, wherein the oral dose of eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered with food.

24. The method of any one of claims 2-22, wherein the oral dose of eperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof is administered under fasting conditions.

25. The method of the above claim further comprising administering to the human subject a rifamycin or a hydrate, solvate or pharmaceutically acceptable salt thereof.

26. The method of claim 25, wherein the rifamycin is rifampin, rifabutin, rifapentine, or rifaximin.

27. The method of claim 25, wherein the rifamycin is rifampin, which is administered to the human subject at an oral dose of about 5 mg / kg to about 15 mg / kg.

28. The method of claim 27, wherein rifampin is administered at an oral dose of about 9 mg / kg to about 11 mg / kg.

29. The method of claim 25, wherein the rifamycin is rifampin, which is administered at an oral dose of about 425 mg to about 625 mg.

30. The method of claim 25, wherein the rifamycin is rifabutin, which is administered in an oral dose of about 125 mg to about 325 mg.

31. The method of claim 25, wherein the rifamycin is rifabutin, which is administered at an oral dose of about 125 mg to about 175 mg, or about 275 mg to about 325 mg.

32. The method of claim 25, wherein the rifamycin is rifabutin, which is administered in an oral dose of about 150 mg, or about 300 mg.

33. The method of the above claim further comprising administering azithromycin or a hydrate, solvate or pharmaceutically acceptable salt thereof.

34. The method of claim 33, wherein azithromycin is administered to the human subject at an oral dose of about 225 mg to about 525 mg.

35. The method of claim 33, wherein azithromycin is administered to the human subject at an oral dose of about 250 mg, or about 500 mg.

36. The method of any one of claims 1-32, further comprising administering clarithromycin or a hydrate, solvate, or pharmaceutically acceptable salt thereof.

37. The method of claim 36, wherein clarithromycin is administered to the human subject at an oral dose of about 475 mg to about 1025 mg.

38. The method of claim 36, wherein clarithromycin is administered to the human subject at an oral dose of about 1000 mg.

39. The method of claim 36, wherein clarithromycin is administered to the human subject twice daily, and wherein each oral dose is from about 475 mg to about 525 mg.

40. The method of claim 36, wherein clarithromycin is administered to the human subject twice daily, and wherein each oral dose is about 500 mg.

41. The method of the above claim further comprising administering amikacin to the human subject.

42. The method of claim 41, wherein amikacin is administered at an intravenous dose of about 5 mg / kg to about 30 mg / kg.

43. The method of claim 41, wherein amikacin is administered at an intravenous dose of about 10 mg / kg to about 15 mg / kg.

44. The method of claim 41, wherein amikacin is administered at an intravenous dose of about 15 mg / kg to about 25 mg / kg.

45. The method of claim 41, wherein amikacin is administered at an intravenous dose of about 475 mg to about 525 mg.

46. ​​The method of claim 41, wherein amikacin is administered in an intravenous dose of about 500 mg.

47. The method of claim 41, wherein amikacin is administered in an inhaled dose of about 580 mg to about 600 mg.

48. The method of claim 41, wherein amikacin is administered in an inhaled dose of about 590 mg.

49. The method of claim 41, wherein the amikacin is a liposomal suspension.

50. The method of any one of claims 13-49, wherein the method further comprises: Prior to the first administration of the dosage regimen, assessing the human subject for markers of infection, wherein the marker of infection is a quantitative colony count and / or a chest CT scan to obtain a baseline assessment, and After the first administration of the dosage regimen, assessing the human subject for markers of infection to obtain a response assessment, wherein the infection marker selected for said response assessment is the same as the infection marker selected for said baseline assessment, comparing the baseline assessment and the response assessment, and The positive treatment response is determined to be achieved when the response assessment is an improvement relative to the baseline assessment.

51. The method of claim 50, wherein there is more than one response assessment.

52. The method of any one of claims 13-49, wherein the method further comprises: Prior to the first administration of the dosage regimen, assessing the human subject for markers of infection, wherein the marker of infection is a quantitative colony count and / or a chest CT scan to obtain a baseline assessment, and After the first administration of the dosage regimen, assessing the human subject for markers of infection to obtain a first response assessment, wherein the infection marker selected for the first response assessment is the same as the infection marker selected for the baseline assessment, comparing said baseline assessment and said first response assessment, and The positive treatment response is determined to be achieved when the first response assessment is an improvement relative to the baseline assessment.

53. The method of claim 52, wherein the response assessment occurs at the end of a dosing regimen or prior to a repeated dosing regimen.

54. The method of claim 52, wherein the infection marker is a sputum sample or an induced sputum sample, and the response assessment is performed every about 21 days to about 35 days after the first dose of each dosage regimen for about 84 days to about 166 days, and the positive treatment response is when the quantitative colony count in the response assessment is lower than one or more classification scores of the quantitative colony count in the baseline assessment.

55. The method of the above claim, wherein the nontuberculous mycobacterium grows rapidly.

56. The method of claim 55, wherein the nontuberculous mycobacterium is fast growing and is selected from the group consisting of Mycobacterium abscessus, Mycobacterium arabifolia, Mycobacterium dearomatum, Mycobacterium bacteremicum, Mycobacterium parasitica, Mycobacterium bourgera, Mycobacterium fast yellow, Mycobacterium chelonae, Mycobacterium saffron, M. franklinii, Mycobacterium fujianensis, Mycobacterium hippocampus, Mycobacterium insubriae, Mycobacterium iraniensis, Mycobacterium littoralis, Mycobacterium lat, Mycobacterium muriaceae, Mycobacterium flavum, Mycobacterium rubrum, Mycobacterium ferruginosa, Mycobacterium salmoniphilum, Mycobacterium sedimentum, or Mycobacterium sette.

57. The method of the above claim, wherein the nontuberculous mycobacterium is slow growing.

58. The method of claim 57, wherein the nontuberculous mycobacterium is slow growing and is selected from the group consisting of Mycobacterium algeriensis, Mycobacterium als, Mycobacterium aarhus, Mycobacterium bouches du rhône, Mycobacterium ingelbeck, Mycobacterium europeum, Mycobacterium fraga, Mycobacterium heraklion, Mycobacterium intracellulare subsp. intracellulare, Mycobacterium koreana, Mycobacterium kumamoto, Mycobacterium kyorin, Mycobacterium leprae lepromatosis, Mycobacterium flanders, Mycobacterium lombardi, Mycobacterium menten Mycobacterium spp., Mycobacterium massa, Mycobacterium minnesota, Mycobacterium niemehke, Mycobacterium paraffinum, Mycobacterium paragordonii, Mycobacterium parakoreanum, Mycobacterium paraseoulii, Mycobacterium paraterrestris, Mycobacterium ryadiana, Mycobacterium sungjenkorea, Mycobacterium seoulii, Mycobacterium sherry, Mycobacterium shiga, Mycobacterium shinjuku, Mycobacterium simulans, Mycobacterium centralis, Mycobacterium magna, Mycobacterium timonei, Mycobacterium wounds, or Mycobacterium yeongun-dong.

59. The method of the above claim, wherein the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium gordonii, Mycobacterium kansasii, Mycobacterium mucogenes, Mycobacterium exogenum, and Mycobacterium xenopus.

60. The method of the above claim, wherein the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium fortuitum complex, Mycobacterium gordonii, Mycobacterium kansasii, and Mycobacterium xenopi.

61. The method of the above claim, wherein the nontuberculous mycobacterium is Mycobacterium avium complex.

62. The method of the above claim, wherein the nontuberculous mycobacterium is Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium masseillaris, Mycobacterium timonei, Mycobacterium bouches du Rhône, Mycobacterium columbia, Mycobacterium wounds, or Mycobacterium chimaera.

63. The method of the above claim, wherein the nontuberculous mycobacterium is Mycobacterium intracellulare.

64. The method of the above claim, wherein the nontuberculous mycobacterium is M. intracellulare subsp. intracellulare or M. intracellulare subsp. chimaera.

65. The method of the above claim, wherein the nontuberculous mycobacterium is Mycobacterium avium.

66. The method of the above claim, wherein the nontuberculous mycobacterium is M. avium subsp. Avium, M. avium subsp. Hominissium, M. avium subsp. silvaticum, or M. avium subsp. Paratuberculosis.

67. The method of the above claim, wherein the human subject has been administered at least one prior NTM therapy that was not eperborole.

68. The method of the above claim, wherein the human subject has been administered at least two prior NTM therapies, none of which were eperborole.

Citation Information

Patent Citations

  • Speckle reduction method and apparatus

    US20110031384A1

  • Boron-containing small molecules

    US7816344B2

  • Process for preparing benzoxaboroles

    US9243003B2

  • Boron-containing small molecules

    WO2008157726A1

  • Process for preparing benzoxaboroles

    WO2011127143A1